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ABSTRACT
IMPACT OF PRODUCT VARIETY ON INVENTORY
PERFORMANCE: AN EMPIRICAL ANALYSIS OF
PHARMACEUTICAL AND MEDICAL DEVICE
INDUSTRIES
Ali Yag˘mur Aydınlı
M.S. in Industrial Engineering
Supervisor: Asst. Prof. Dr. Alper S¸en
September, 2012
In this thesis, we construct empirical models to analyze the effect of various
financial measures and product variety on inventory performance. We apply mul-
tiple regression models and simultaneous equations models using 2010 financial
data for 128 U.S. firms in pharmaceutical and medical device industries. Using
multiple regression models, we investigate the correlation of inventory turnover
with product variety, gross margin, capital intensity and type of the firm. Prod-
uct variety data are obtained from U.S. Food and Drug Administration. The
best multiple regression model explains 38.50% of the total variation in inventory
turnover and we observe that inventory turnover is negatively correlated with
product variety. Since inventory turnover is the ratio of cost of goods sold (sales)
to inventory level, a change in product variety might have an effect both on in-
ventory level and cost of goods sold. In order to investigate the effects of product
variety on cost of goods sold and inventory level separately, we employ simulta-
neous equation models. The best simultaneous equation model explains 96.22%
of the variation in inventory level and shows that inventory level is positively
associated with product variety.
Keywords: Inventory turnover, inventory level, product variety.
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O¨ZET
U¨RU¨N C¸ES¸I˙TLI˙LI˙G˘I˙NI˙N ENVANTER
PERFORMANSINA ETKISI: I˙LAC VE TIBBI˙ CI˙HAZ
ENDU¨STRI˙SI˙ AMPI˙RI˙K ANALI˙ZI˙
Ali Yag˘mur Aydınlı
Endu¨stri Mu¨hendislig˘i, Yu¨ksek Lisans
Tez Yo¨neticisi: Asst. Prof. Dr. Alper S¸en
Eylu¨l, 2012
Bu c¸alıs¸mada, c¸es¸itli finansal o¨lc¸u¨tlerin ve u¨ru¨n c¸es¸itlilig˘inin envanter per-
formansı u¨zerinde etkilerini analiz eden ampirik modeller gelis¸tirilmis¸tir. Bu
kapsamda, A.B.D sag˘lık sekto¨ru¨nde faaliyet go¨steren 128 ilac¸ ve tıbbi cihaz
firması verileri, c¸oklu regresyon modelleri ve es¸-zamanlı denklemler model-
leri kullanılarak analiz edilmektedir. C¸oklu regresyon modelleri ile, envanter
do¨nu¨s¸u¨m hızının; bru¨t kaˆr marjı, sermaye yog˘unlug˘u, u¨ru¨n c¸es¸itlilig˘i ve fir-
manın faaliyet go¨sterdig˘i sekto¨r arasındaki korelasyonları incelenmektedir. U¨ru¨n
c¸es¸itlilig˘i verileri Amerikan Gıda ve I˙lac¸ Kurumu’ndan (FDA) alınmıs¸tır. En
iyi c¸oklu regresyon modeli, envanter do¨nu¨s¸u¨m hızındaki varyasyonun %38,5’ini
ac¸ıklayabilmektedir. Ayrıca, u¨ru¨n c¸es¸itlilig˘i ile envanter do¨nu¨s¸u¨m hızı arasındaki
korelasyonun, beklendig˘i u¨zere, negatif oldug˘u go¨ru¨lmu¨s¸tu¨r. Fakat, envanter
do¨nu¨s¸u¨m hızı satıs¸ların maliyetinin envanter seviyesine oranı oldug˘undan, u¨ru¨n
c¸es¸itlilig˘inin hem satıs¸ların maliyetine hem de envanter seviyesine etkisi bulun-
maktadır. U¨ru¨n c¸es¸itlilig˘inin, envanter seviyesine ve satıs¸ların maliyetine olan etk-
isini ayrı ayrı analiz edebilmek ic¸in es¸-zamanlı denklemler modelleri kullanılmıs¸tır.
En iyi es¸-zamanlı denklemler modelinin envarter seviyesindeki varyasyonunun
%96,22’sini ac¸ıkladıg˘ı go¨zlemlenmis¸ ve envanter seviyesinin u¨ru¨n c¸es¸itlilig˘i ile
bag˘lantısının pozitif oldug˘u go¨ru¨lmu¨s¸tu¨r.
Anahtar so¨zcu¨kler : Envanter do¨nu¨s¸ hızı, envanter seviyesi, u¨ru¨n c¸es¸itlilig˘i.
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Chapter 1
Introduction
Drug market is a rapidly growing market. Standard and Poor’s estimates that
the generic drug market will grow from $ 83 billion in 2009 to $ 135 - $ 150 billion
in 2015 [1]. The largest share of the market belongs to Teva with 21%. Novar-
tis AG (10%), Mylan Inc. (6%), Watson Pharmaceuticals Inc. (6%), STADA
Arzneimittel AG (3%), Actavis (2%), Ranbaxy Laboratories Ltd. (2%) making
up the pack following Teva. The rest of the market is shared by many firms,
which add up to 50% [1].
Prescription drugs are another key driver of growth for health care firms.
Pfizer, AstraZeneca, Bristol-Myers and GlaxoSmithKlein are the top sellers of
prescription drugs. Many drugs’ patents will expire in the coming years, the
prescription drugs will become generic drugs, hence they will be open for com-
petition. Therefore, health care companies will be considering new cost cutting
strategies for growth. The cost cutting initiatives include but are not limited to
reduction of overhead cost, reduction of inventories held and other cost cutting
programs. We analyze the inventory management and supply chain strategies
that will benefit decision makers in the industry and guide them in their search
for efficiency and cost cutting strategy.
In this scope, we have obtained public financial data of the related companies
from Wharton Research Data Services’s (WRDS) [2] and product variety data
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from Food and Drug Administration’s web site. FDA monitors the manufactur-
ing process, the storage process and the transportation process of health care
products in USA. In this highly regulated environment, it is becoming difficult
for companies to cut costs and effectively manage the company. Apart from cut-
ting overhead costs, to get one step ahead in a highly competitive environment,
companies need to improve their supply chain structures and inventory systems.
Hence, optimizing and understanding the variables that effect inventory turnover
and inventory level becomes a critical issue for success.
Inventory managers usually measure the inventory turnover, which is the ratio
of cost of goods sold to the inventory level, to understand the performance of the
company’s inventories. The inventory turnovers of major firms vary widely from
each other, representing opportunities in efficiently managing inventories and
the related supply chain. For example, the annual inventory turnover of Teva
Pharmaceutical Industries Ltd. is around 1.5530, whereas the values for Mylan
Inc., Watson Pharmaceuticals Inc. and Bristol-Myers Squibb Co. are around
2.2574, 2.9576 and 3.6710, respectively.
Even though other factors within a company can influence inventory turnover,
we are mainly interested in the effects of product variety. To our knowledge a
research of this scale has not been put forward.
Our thesis uses public financial data obtained from Wharton Research Data
Services’s (WRDS) CompuStat Database and product variety data obtained from
FDA to understand and evaluate the relationship between the inventory turnover
and product variety. The WRDS provides gross margin, capital intensity, inven-
tory level, cost of goods sold and sales data of the chosen firms from medical
device and pharmaceutical industries. We use the existing literature to formulate
the hypothesis and use the data we obtained to draw conclusions about them. We
have set up a similar hypothesis as Gaur et al. [3]. The primary contribution of
this thesis is the inclusion of product variety to explain the variation in inventory
turnover, Hypothesis 3, and inventory level, Hypothesis 4.
To test these hypotheses, first, we apply multiple regression models and ob-
serve that only 30%-39% of the variability in inventory turnover can be explined
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by the variables. Our main findings from the multiple regression models point out
that the inventory turnover rate can be explainable by the exogenous variables.
The best multiple regression model we have can explain approximately 39% of
the variation.
The relationship between product variety and inventory turnover is vague
because a change in product variety affects both cost of goods sold and inventory
level, which together make up the ratio of inventory turnover. One main goal of
this paper is to explain this vague relationship among product variety, inventory
level and cost of goods sold. We develop Hypothesis 4 in order to understand
the relative effect of product variety on inventory levels. We believe that product
variety increases inventory level relatively more than cost of goods sold.
We incorporate simultaneous equations models, in particular two stage least
square estimation to analyze the relationship between product variety and inven-
tory level. The models we built can explain approximately 90 to 96% of the total
variations in inventory level.
This thesis contributes, empirically, to inventory management and supply
chain research in health care industry. As the competition increases in drugs
and devices industry tackling the problem of inventory management becomes a
significant issue. We believe that our model explains the role of product variety
on inventory turnover ratio and inventory level across firms.
The rest of the thesis is organized as follows; in Chapter 2 the pertinent
literature is summarized, in Chapter 3 the methods and models used is explained
throughly, Chapter 4 provides information on the data sources we used, Chapter
5 describes the hypotheses, in Chapter 6 we construct multiple regression models
and simultaneous equations models. After giving each multiple regression model’s
results we test for the regression assumptions for each model. For SEM, we solve
them by using two stage least square estimation, test for endogeneity bias and
overidentification then summarize our findings. Finally, we draw conclusions of
the results and possible extensions in Chapter 7.
3
Chapter 2
Literature Review
In this chapter, we review the important empirical and theoretical literature re-
lated to our research. Inventory management has been an area of interest in
operations research. There is a vast amount of literature in this area (start-
ing from the EOQ model that was developed nearly a century ago and advanced
models that include stochastic demand, multiple products and multiple echelons).
However, empirical research in this area is relatively new. We have reviewed the
papers that use actual macroeconomic data and theoretical papers, whose main
focus is inventory management and supply chain management.
Gaur et. al [3] incorporate cost of goods sold, inventory level and gross margin
as endogenous variables to improve the firm-level sales forecast. Data of retailers
are driven from the CompuStat database. The data consist of 230 observations
from 2004 to 2007 of retail firms. Authors define simultaneous equations model to
represent the forecasting model’s basis. The authors use the analysts’ consensus
forecasts to compare with their forecast results. Absolute percentage error (APE)
and mean absolute percentage error (MAPE) are used to compare the results with
analysts’ forecasts. Furthermore, the authors investigate the reasons behind the
differences between their forecasts and analysts’ forecasts by examining inventory
and gross margin residuals. The authors have managed to get more accurate
forecasts than the analysts, since analysts do not take into account the inventory
and gross margin data in their sales forecasts. However, the authors fail to
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incorporate the effects of product variety on inventory, cost of goods sold and
gross margin.
Gaur et. al [4] develop econometric models to analyze the effect of gross mar-
gin, capital intensity and sales surprise on inventory performance. The authors
use data from 311 publicly listed retail firms to test their hypothesis. The authors
manage to show that inventory turnover, in retail services, have a high correla-
tion with gross margin, capital intensity and sales surprise. The paper proves
that as gross margin increases inventory turnover decreases, capital intensity and
sales suprise are positively correlated with inventory turnover. Moreover, they
conclude that inventory should not be treated as the only variable that is used
in performance analysis. In our thesis, we prove authors’ Hypothesis 1 and Hy-
pothesis 2 using multiple regression models for health care industry. The authors
suggest to use product variety as another explanatory variable. We have extended
this study and incorporated product variety as one of the explanatory variables
in multiple regression models to analyze its effect on inventory turnover.
Rajagopalan and Malhotra [5] study the trends in finished goods materials
and work in process inventory ratios of 20 U.S manufacturing companies during
1961-1994. The authors use a simple linear regression model to investigate the
rate of change in inventory ratios over years and setup hypotheses to test the
regression model. The hypothesis tests formed are related to the inventory ra-
tios and their relation with the time period and the respective industry sector.
The article goes on to find out that as the inventory theory improved, materials
and work in process inventories started to decrease in most of the cases stud-
ied. Moreover, industry sectors such as furniture and fabricated metal products
showed improvement in work-in-process inventory ratios, while sectors such as
textiles, lumber, printing/publishing, rubber, and machinery showed improve-
ment in work-in-process inventory, finished goods inventory and materials and
supplies inventory.
Cachon and Olivares [6] measure the effect of days of supply, sales rate, pro-
duction flexibility and number of dealerships on finished goods inventory levels in
U.S. auto manufacturing industry, mainly comparing Toyota, Chrysler, Ford and
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GM. The authors find that, the differences between the levels of inventory among
Toyota, Chrysler, Ford and GM arise from differences in production flexibility
and number of dealerships. Flexibility in production enables the firm to easily
track the demand of the customer. The authors argue that this can be accom-
plished by changing the production levels when there is a change in sales level.
Fewer number of dealerships allows the firms to pool demand in fewer locations.
The paper concludes that Toyata has these set of advantages, which enables it to
have a competitive advantage over rival firms in U.S. auto industry.
Roumiantsev and Netessine [7] examine absolute and relative inventories of
companies based on an empirical data of 722 U.S. public companies for the years,
between 1992-2002. The authors’ multiplicative model explains 85 percent of the
absolute inventory in these firms. Moreover, the paper argues that as gross mar-
gin increases so does the inventory level. Companies that can attain economies
of scale have less inventory in relative terms. Therefore, the paper concludes
that aggregate inventory level is positively linked to mean demand and demand
uncertainty. Additionally, relative inventory levels are negatively associated with
company size, since both absolute and relative inventory increase with lead times
and product margins.
Cachon et. al [8] study the bullwhip effect using empirical industry level U.S
data. The bullwhip effect is defined as the increase in variability of demand as
one goes upstream in the supply chain. It is usually observed in forecast driven
distribution channels. The paper conducts its empirical research on 6 retail, 18
wholesale and 50 manufacturing industry sectors, whose data are taken from the
U.S Census Bureau. The authors measure the variance of production and the
variance of demand of customers in downstream for each sample. The paper
concludes that there is no bullwhip effect among retailers and manufacturers.
They go on to find that seasonality has great influence on bullwhip effect.
Kekre and Srinivasan [9] explore the advantages and disadvantages of having
a broader product variety using 1400 firms. The authors use Strategic Business
Unit data obtained from Profit Impact Strategy (PIMS) and use econometric
analysis to test the hypotheses. One of the major hypothesis the authors put
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forward is; as product variety increases so does level of inventory. But they, also,
believe that an increase in product variety will increase the market share of the
firm and enable it to use economies of scale by pushing suppliers to meet its terms,
thus, reducing inventory level. But we mainly believe that variety increase brings
an increase in inventory level, in health care industry. The key finding of the
authors is; higher product variety leads to a higher market share and increased
profitability. However, the cost effect of having higher product variety cannot be
tested using empirical analysis.
Ton and Raman [10] analyze the effect of product variety on the level of in-
ventory held and the amount of sales made in Borders stores across USA. The
authors believe that having high product variety and high inventory levels lead
to higher sales in stores. However, there are some drawbacks of maintaining a
high variety and a high level of inventory. The authors prove with an econometric
model that an increase in product variety leads to an increase in phantom prod-
ucts, i.e, the products that are in the inventory but not on the shelf, therefore the
customers are not able to make a purchase. Increase in inventory levels leads to
an increase in the percentage of unidentified phantom product percentage by cus-
tomers. Lastly, as the number of phantom products increases there is a decrease
in the sales of the related store. The paper uses regression analysis to prove the
hypothesis on phantom products.
Mahajan and van Ryzin [11] use a multinomial logit model to identify the
purchase quantities for each of the product’s varieties. The paper tries to capture
the trade-off between the costs of having a high product variety and a low variety.
The authors use a stochastic choice process for customer purchase decision using
a multinominal logit random utility model. For the retailers’ supply process the
authors use the newsboy model. The paper proves that high variety becomes
profitable in high volume of business because big businesses can utilize economies
of scale more efficiently.
We also analyze the theoretical work behind the variables effecting inventory
levels. These papers include Marvel and Peck [12], Balakrishnan et. al [13] and
Cachon [14]. These papers enable us to develop our hypotheses and effectively
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identify and measure variables that induce inventory management systems.
Marvel and Peck [12] study the vertical misalignment of inventories and
demonstrate its impact on product variety. The paper uses game theory to ana-
lyze the problem. The game consists of three stages; choice of the manufacturer
wholesale price, choice of price for retailer for each of the product varieties and
choice of the products that retailers want to carry. The game is studied over an
infinite time horizon. Every retailer must first choose its price then its inventory
level of the product. The paper concludes that a retailer carrying few product
varieties and high inventory turnover can achieve high market share. The authors
suggest that high inventory turnover ratio can be achieved by reducing prices to
keep the inventory levels low.
Balakrishnan et. al [13] analyze the effect of stock keeping on firm’s profit
level. The authors define the objective function as a profit maximization problem.
Then, they use EOQ model to incorporate the effects of cost and revenue ingre-
dients. The paper finds that the excess inventory can, indeed, increase demand.
Additionally, the authors prove that for items that have low holding costs, it is
optimal to have inventory levels above the reorder level. Since the classical EOQ
model does not include the demand stimulation of inventory it orders too little
and too frequent making it a suboptimal policy.
Cachon [14] investigates supply chain demand volatility using a model with a
single supplier and N retailers with stochastic demand. The paper identifies that
using scheduled ordering policies, like ordering every T periods with an integer
multiple of a fixed batch size, usually lowers the total supply chain costs. More-
over, if the supplier’s demand volatility decreases the supplier’s average inventory
will decrease. In order to do this, two strategies have been identified. First, one
can increase the number orders by increasing the period, T, and reduce the order
sizes. Second, the retailer can balance its order intervals. However, the authors
note that by increasing the order period the supply chain costs increase.
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Chapter 3
Methodology
Our main contribution in this research is to study the effect of product variety
in addition to gross margin, capital intensity and cost of goods sold on inventory
performance of a firm to identify the effects on inventory turnover and firm’s per-
formance. We use empirical data retrieved from Wharton Research Data Services
(WRDS) [2], CompuStat database. We limit our research to analyzing pharma-
ceutical drug and medical device companies. We use STATA software [15] to
implement the multiple regression method and the simultaneous equation mod-
els. We use the STATA command regress for multiple regressions and ivregress
2sls to handle simultaneous equation models. In this chapter we review the meth-
ods used in our analysis.
3.1 Multiple Regression
We have used the multiple linear regression model to test some of our hypoth-
esis. This model has the advantage of identifying the independent variables that
have an effect on the dependent variable. The generic form of a multiple linear
regression model is given as follows;
yt = β1 + β2xt2 + β3xt3 + ...+ βkxtk + t. (3.1)
In the above equation yt is the dependent variable and xt2, xt3, ..., xtk are called
independent variables. The t term is the disturbance term or the error term in
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the equation. Greene [16] gives the assumptions of this model as:
1. Linearity; the linear relationship between the dependent variable and the
independent variables.
2. Full Rank; there is no or little correlation between the independent vari-
ables.
3. Exogeneity and independent variables; the expected value of the error
term given all the independent variables equal to zero. That is;
E[t|xt2, ..., xtk] = 0,
meaning that the independent variables do not carry information about i.
4. Homoscedasticity and non-autocorrelation; i the error terms, have the
same variance, σ2, and they are uncorrelated with the other error terms j.
5. Normal distribution; the error terms are normally distributed.
Furthermore, since the dependent variable, yt depends on the random error term
t, it is also a random variable. The properties of the dependent variable yt are
as follows:
1. When we take the expected value of the multiple regression model, since
E[t] = 0, the model becomes;
E[yt] = β1 + β2xt2 + ...+ βkxtk.
2. var(yt) = σ
2. The variance of the dependent variable yt does not differ with
each and every observation.
3. cov(yt, ys) = 0, meaning that any two observations on the dependent vari-
able are uncorrelated. If any of the observations is above the expected value
of the dependent variable E[yt], any other subsequent observation will be above
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E[yt].
4. The values of the dependent variable, yt, are assumed to be normally dis-
tributed.
The multiple regression analysis enabled us to estimate, forecast and construct
test statistics to determine the significance of the independent variables on the
model using hypothesis testing.
In order to fully understand the least square estimation procedure consider
the following multiple regression model with two independent variables:
yt = β1 + β2xt2 + β3xt3 + t.
Carter [17] describes the least square estimation procedure for the multiple regres-
sion model as a procedure that minimizes the sum of squared differences between
the observed values of yt and their expected values. Thus, the above multiple
regression model becomes;
E[yt] = β1 + xt2β2 + xt3β3.
Then, we minimize the sum of square function S(β1, β2, β3) that is;
S(β1, β2, β3) =
T∑
t=1
(yt − β1 − β2xt2 − β3xt3)2. (3.2)
The solution to the least square estimation is the least square estimates b1,b2,b3.
The deviations of each variable from their means are;
y∗t = yt − y¯, x∗t2 = xt3 − x¯3. (3.3)
Thus, b1,b2 and b3 can be found by solving;
b1 = y¯ − b2x¯2 − b3x¯3, (3.4)
b2 =
(
∑
y∗t x
∗
t2)(
∑
x∗t3)− (
∑
y∗t x
∗
t3)(
∑
x∗t2x
∗
t3)
(
∑
x∗2t2 )(
∑
x∗2t3 )(
∑
x∗t2x
∗
t3)
2
, (3.5)
b3 =
(
∑
y∗t x
∗
t3)(
∑
x∗2t2 )− (
∑
y∗t x
∗
t2)(
∑
x∗t3x
∗
t2)
(
∑
x∗2t2 )(
∑
x∗2t3 )(
∑
x∗t2x
∗
t3)
2
. (3.6)
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These formulas are used to calculate the least square estimates for (3.2) using the
given data. In implementation, we use STATA software to calculate b1, b2 and b3.
To estimate the variance (σ2) of the error term, t an estimation procedure has
been developed. This procedure uses the least square residuals, which represents
the sample information about the error term. The least squares residuals method
for (3.2) are written as;
̂t = yt − ŷt = yt − (b1 + xt2b2 + xt3b3), (3.7)
An estimator of σ2 would be
σ̂2 =
∑
̂t
2
T −K , (3.8)
where K is the number of parameters estimated in the multiple regression model
and T is the sample size.
In the multiple regression model it is assumed that the least square estima-
tors are unbiased. If the variances are high, then the probability of producing
estimates close to the true parameter value will be higher. For example when we
have only three parameters to estimate, meaning K = 3 we can formulate the
variance and covariance of the least square estimator of b2 as such;
var(b2) =
σ2∑
(xt2 − x2)2(1− r223)
, (3.9)
where r23 is the correlation coefficient between the values x2 and x3. The formula
of the correlation coefficient, r23 is given as;
r23 =
∑
(xt2 − x2)(xt3 − x3)√∑
(xt2 − x2)
∑
(xt3 − x3)2
. (3.10)
Other variances and covariances have similar formulas. Factors affecting the vari-
ance of b2 can be listed as:
1. Since variance (σ2) is the uncertainty in the model, the greater the vari-
ance of the least square estimator is, the greater the error variance will be.
2. As the sample size increases the variance of the least square estimator de-
creases. Because the larger the sample size is the larger the value of
∑
(xt2 − x2)2
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will be. Thus, the more accurate the estimator becomes.
3. The larger
∑
(xt2 − x2)2 becomes, which is the variation of the explanatory
variable around its mean, the smaller the variance of the least square estimator.
4. As the correlation coefficient, r23 grows larger, variance of b2 increases.
For example, if we wanted to estimate three parameters of a multiple regression
model the variance and covariance matrix, cov(b1, b2, b3) would be like:
cov(b1, b2, b3) =

var(b1) cov(b1, b2) cov(b1, b3)
cov(b1, b2) var(b2) cov(b2, b3)
cov(b1, b3) cov(b2, b3) var(b3).

3.1.1 Significance Test
We have constructed a hypothesis test to identify the significance of our vari-
ables. The null and alternative hypotheses we have specified are;
Ho: variable is significant
Ha: variable is not significant
Based on the test statistics we either reject the null hypothesis or fail to reject it.
Moreover, when evaluating the results of the hypothesis tests we have calculated
the p-value in order to either reject or accept the null hypothesis. If the p-value
of a hypothesis test is smaller than the chosen significance level, α, then the
conclusion is to reject the null hypothesis. Consequently, if the p-value is greater
than the significance level we fail to reject the null hypothesis. For all of our
hypotheses, we have tested whether the independent variable has an effect on the
dependent variable or not.
We take the logarithms of the variables in order to smooth out the fluctua-
tions in our observations. This usually gives us a more reliable estimation.
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3.1.2 R-Squared and Adjusted R-Squared
In a multiple regression model, R2 measures the proportion of variation in the
dependent variable explained by all the explanatory variables in the model [17].
The logic and formulas behind R2 in a multiple linear regression model is exactly
the same as the simple linear regression model. To explain R2, consider a simple
regression model;
yt = β1 + β2xt + t. (3.11)
For this model, R2 states how much of the variation in xt can explain the variation
in the dependent variable, yt. To measure the variation in yt we divide the
dependent variable, yt, into explainable and unexplainable components. Further
assume that;
yt = E(yt) + t, (3.12)
where t is the unexplainable portion of yt, while E[yt] = β1+β2xt is the explain-
able portion of the dependent variable. We estimate β1 and β2 by decomposing
yt into;
yt = ŷt + ̂t, (3.13)
where ŷt = b1 + b2xt and ̂t = yt − ŷt.
Then, by subtracting sample mean of the least squares fitted line, y from both
sides of the equation
yt − y = (ŷt − y) + ̂t (3.14)
In the above statement (ŷt − y) is the explained part of the equation, while ˆt is
the noise part. Moreover, to measure the total variation in a variable we square
the differences between yt and its mean value y and sum it over the entire sample.
14
That is; ∑
t
(yt − y)2 =
∑
t
[(ŷt − y) + ̂t]2
=
∑
t
(ŷt − y)2 +
∑
t
̂2t + 2
∑
t
(ŷt − y)̂t
=
∑
t
(ŷt − y)2 +
∑
t
̂t (3.15)
Since the term
∑
(ŷt − y)̂t = 0 it has been dropped out of (3.15). In order to
calculate the R2 we need to identify the sums of squares;
1. Total sum of squares, SST , is the measure of total variation in y about its
sample mean and it is given as;
∑
t (yt − y)
2. Explained sum of squares, SSR, is the part of total variation in the dependent
variable, y, about its sample mean that is explained by the regression model and
is shown by
∑
(ŷt − y)2
3. Error sum of squares, SSE, is the total variation in y about its mean that
cannot be explained by the regression
∑
̂2t .
The equation (3.15) becomes SST = SSR + SSE. The degrees of freedom
for the above sum of squares are given in the below table:
Source of Sum Mean
Variation DF of Squares Square
Explained 1 SSR SSR/1
Unexplained N-2 SSE SSE/(N-2)
Total N-1 SST
Table 3.1: Analysis of Variance
In Table 3.1, the first row of the Mean Square column is the ratio of SSR to
its degrees of freedom and the second row is the ratio of SSE to its degrees of
freedom, which equals to σ̂2.
Lastly, the proportion of variation in the dependent variable, y, is explained
by x within the regression model, is shown by
R2 =
SSR
SST
= 1− SSE
SST
(3.16)
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If R2 equals to 1 then all the sample data fall on the fitted least squares line
and SSE =0. If y and x are not correlated then the least square fitted line is
horizontal and identical to y and SSR = 0 in which case the R2 = 0. When
0 < R2 < 1, the percentage of variation in the dependent variable, y, about its
mean that is explained by the regression model [17].
3.3 Simultaneous Equations Models
We, also use simultaneous equations models (SEM). Simultaneous equations
models consist of a set of equations rather than just a single equation and there are
two or more dependent variables in each model . Ordinary least square estimation
procedure is not appropriate in these models since these models do not adress
endogeneity bias. In order to fully understand the simultaneous equations models,
consider a simple SEM such as [18]:
y1 = α0 + α1x1 + α2x2 + ...+ αkxk + β1y2 + , (3.17)
y2 = β0 + β1x1 + β2x2 + ...+ βkxk + βk+1z1 + ...+ βk+mzm + ν, (3.18)
y2 = yˆ2 + ν, (3.19)
where y2 is an endogenous variable. There arem instruments, namely z1, z2, ..., zm
that are correlated with y2. Let z = (1, x1, ..., xK , z1, ..., zm). yˆ2 is a linear projec-
tion of y2. Note that, yˆ2 is not correlated with  but ν is correlated with . When
there is a small change in the error term, say , this effect is directly transmitted
to the value of xk. The failure of the least square estimation for the first equa-
tion arises cause of the effects triggered by the changes in the error terms. This
happens because we do not observe the change in the error term but rather the
change in xk, which results from its correlation with the error term. The least
square estimator of βk will underestimate/overestimate the true parameter value
in the model. Therefore, the least square estimator of parameters lead to a biased
and inconsistent estimator, due to the correlation between the random error and
endogenous variables on the right hand side of the equation.
Apart from the classic assumptions of least square we postulate that the set
of variables, z, have two properties:
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1. For vector z, E(z′) = 0.
2. Relevance: z’s are correlated with the independent variable, X.
Then yˆ2 with Z can be written as;
Yˆ2 = (Zβˆ) = Z(Z
′Z)−1Z ′Y2. (3.20)
Note that Z is a matrix. We use y2 as a variable in X and project X with Z.
That is;
Xˆ = Z(Z ′Z)−1Z ′X, (3.21)
The IV estimation becomes;
ˆβ2SLS = (Xˆ
′X)−1Xˆ ′Y. (3.22)
This is the two stage least square estimator.
The properties of two stage least squares are: 1. Two stage least square has
a consistent estimator.
2. Two stage least square is normally distributed in large samples.
3. Variance and covariance of two stage least square estimators are known.
3.3.1 Endogeneity Test
We use Durbin-Wu-Hausman statistics to determine whether the regression
analysis has any autocorrelation.
The Durbin-Wu-Hausman test was proposed first by Durbin in 1954[19], then
by Wu[20] in 1973 and separately by Hausman[21] in 1978. The test allows to
decide for the presence of a correlation between an explanatory variable and the
error term, i. The test is performed by comparing the estimate of the ordinary
least square estimation and the estimate from the IV estimation, in our case two
stage least square estimation. Therefore, the test statistics becomes:
H = (βˆIV − βˆOLS)T [ ˆAvar(βˆIV )− ˆAvar(βˆOLS)]−1(βˆIV − βˆOLS) ∼ χ2J
where J is the number of endogenous regressors. Note that, Avar is the asymp-
totic variance-covariance matrix.
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The hypothesis test is:
Ho : cov(x, i) = 0 (3.23)
Ha : cov(x, i) 6= 0 (3.24)
If the null hypothesis cannot be rejected, we conclude that the instrumental
variables are consistent otherwise if the hypothesis test becomes statistically sig-
nificant then the chosen instruments are not valid.
Furthermore, Hill [17] describes an alternative method, where the author uses
the following regression method to explain it:
yt = β1 + β2xt + t. (3.25)
We want to know whether x is correlated with the error term,  that is cov(x, ) =
0. To calculate the correlation we use zt1 and zt2 as instrumental variables for x.
Hill [17] carries out a couple of steps; firstly incorporates the instrumental vari-
ables zt1 and zt2 and obtain the residuals. Secondly, uses the residuals computed
in the first step as a dependent variable in the above equation. Then, estimates
the regression by least square estimation and uses the t-test for the hypothesis
significance. Additionally, if more than one variable is suspected of having a cor-
relation with the error term, one must use an F -test of joint significance of the
coefficients on the included residuals.
We also need to test the endogeneity that arises due to autocorrelation with
the 2SLS method.
In STATA we use “estat endog” command to test endogeneity problem. The
estat endog command reports us a Durbin chi-square and a Wu-Hausman F -
statistics and the respective p-values with null hypothesis being;
Ho: variables are exogenous
Ha: variables are endogenous
If the p-value is less than our confidence interval we reject the null hypothe-
sis, which means that the instrumented variable is endogenous.
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3.3.2 Overidentification Test
We use “estat overid” command of STATA to test the validity of the instru-
ments used in the model. The estat overid command reports a Sargan chi-square
and a Basmann chi-square statistics and the respective p-values. Sargan and
Basmann chi-square test checks whether the statistical model used over identifies
restrictions, meaning if the instruments used are valid. If the null hypothesis
cannot be rejected then the instruments used are valid. Moreover, if the p-value
is greater than our confidence interval we conclude that the over identifying re-
striction is valid.
3.3.3 Significance Tests: Wald Statistics
STATA, also, gives the results of the Wald statistics for two stage least square
estimation procedure. Wald test is used to test one or more restrictions in a
regression model. For example, consider the OLS estimated equation
Yˆ = βˆ1 + βˆ2X2 + βˆ3X3
Suppose that we consider testing the restriction β1 + β2 = 1. We estimate the
variance with
υ˜2 = σ˜2(x22 + x33 + 2x23)
The square of a standard normal distribution is a χ2 distribution with one degree
of freedom. Thus,
W =
βˆ2 + βˆ3 − 1
υ˜
W is the Wald statistics for the restriction. Wald test can also be utilized to test
more than one restriction.
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Chapter 4
Description of data and variables
For our analysis, we use the U.S pharmaceutical and medical device manufactur-
ing companies’ 2010 data. The dataset is collected from the Wharton Research
Data Services (WRDS) database. In WRDS, we have exerted the “CompuStat
North America- Annual Updates” to obtain the cost of goods sold, inventory, to-
tal asset and current asset amounts of the respective pharmaceutical and medical
device manufacturing companies. Additionally, we have used the Food and Drug
Administration’s (FDA) data on medical devices and pharmaceutical drugs. The
medical device manufacturers’ dataset is obtained from the products and med-
ical procedures downloadable 510(k) files. Data regarding the pharmaceutical
drugs are obtained from the “drug approvals and databases” national drug code
directory.
The FDA databases of medical device manufacturers and pharmaceutical drug
companies’ datasets contain the product varieties of each of the respective firms.
Table 4.1 describes the data obtained from the national drug code directory.
Section 510(k) of FDA requires manufacturers to register their respective medical
devices. The file descriptions for releasable 510(k)s are presented in table 4.2.
The WRDS’s Compustat database has each firm’s data that are classified
via the help of Standard Industry Classification (SIC) codes that are assigned by
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Definition Description
Product NDC : The labeler code and product code of
the related National Drug Code number
Product Type Name : Contains the type of the product and indicates whether
the drug is a human prescription drug or human OTC drug
Proprietary Name : Trade name of the drug
Proprietary Name Suffix : Distinguishes the characteristic of a product
such as extended release (XR) or intravenous (IV) etc.
Dosage Form Name : The dosage form submitted by the company
Non-priorietary Name : Generic name of the drug
Route Name : Describes how the product is used
Starting Marketing Date : The date the marketing of the drug begun
End Marketing Date : The date when the drug will no longer be available
Marketing Category Name : The marketing category chosen by the company
from a list, which contains NDA/ANDA/BLA, OTC etc.
The Application Number : Contains the number reported by the companies that
have the corresponding marketing category
Labeler Name : The name of the company that produces the drug
Substance Name : The active ingredient of the drug
Strength Number : The strength values of the respective drug
Strength Unit : The units of the strength number described preciously
Pharm Classes : The pharmaceutical class categories corresponding
to substance name
DEA Schedule : The assigned DEA schedule number
reported by the company
Table 4.1: Notation and Descriptions of the National Drug Code data
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Definition Description
Applicant : The company, which wants to
approve the medical device
Contact : The name of the respective company
Street1, street2, city, state and zip : The open address of the respective firm
Device Name : The name of the device registered
Date Received : The application date of the drug
Decision Date : The date of the decision taken by the FDA
Decision Column : Decision taken by the FDA for the related drug
Review Advise : Contains the advisory committees decision
on the drug
Product Code : Code given to the respective drug
State or Summary Column : if it is labeled as summary it indicates safety
and effectiveness information is available
from FDA
if it is labeled as statement it indicates that
the information can be obtained from
the applicant firm
Class Advise Committee: The code number under which the
respective product was classified
Type : Indicates the type of 510(k) submission
Third Party Column : Indicates whether or not the application
was reviewed by a third party
Table 4.2: Notations and Descriptions of the 501 (k)data
22
the U.S. Department of Commerce. The U.S. Department of Commerce identifies
pharmaceuticals and medical devices companies by four-digit SIC codes as: phar-
maceutical preparations (SIC:2834), in vitro and in vivo diagnostics substances
(SIC:2835), biological products (no diagnostic substances) (SIC:2836), perfumes,
cosmetics and other toilet preparations (SIC:2844), surgical and medical instru-
ments and apparatus (SIC:3841), orthopedic, prosthetic, surgical appliances and
supplies (SIC:3842), dental equipment and supplies (SIC:3843), x-ray appara-
tus, tubes and related irradiation apparatus (SIC:3844) and electromedical and
electrotherapeutic apparatus (SIC:3845).
The CompuStat database includes respective inventory, cost of goods sold
(COGS), current assets, total assets and sales/turnover ratio of the firms. The
CompuStat database offers ten different inventory valuation methods. The most
common inventory valuation methods used by the pharmaceutical and medical
device manufacturing firms are first in first out (FIFO) and last in first out (LIFO)
methods. Cost of goods sold includes costs incurred during the production of the
goods such as labor, raw material and overhead costs. Even though the COGS
line can vary from company to company, it does not include the research and
development costs for pharmaceutical companies. Current assets are the cash
and other assets that are expected to be realized in short term, which consists of
items realized less than 12 months or used in the production of revenue within
12 months. Sales/turnover ratio is total gross sales minus cash discounts trade
discounts, and sales returns and allowances for the credit given to customers, for
each operating segment. We have collected the financial data for the companies
in accordance with their SICs for the fiscal year 2010.
In our research, we identify the effects of product variety on gross margin,
capital intensity and inventory turnover. Therefore, we match the CompuStat
data with the data obtained from FDA. We have pursued the following steps
to match the data. First, we basically pair the companies with the same name.
Some companies had only a single official name, which make them easier to pair.
However, in the FDA data set some of the firms have multiple names. To give
an example, Roche is registered under the names of Roche, Roche Diagnostic
System Inc., Roche Diagnostics, Roche Diagnostics Corp., Roche Diagnostics
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Corporation, Roche Professional Diagnostics etc. We combine all the Roche data
in the FDA database into a single Roche and match it with Roche Holding AG in
the CompuStat database. Moreover, if the parent company has any subsidiaries
we group the product varieties’ of the subsidiaries under the parent company. The
problem we encountered was that some firms in the CompuStat database did not
match one-to-one with the FDA database. Thus, we eliminated the non-matching
data.
Thereafter, we remove the firms that have product variety less than five. Since,
these firms probably have other goods or services that generate income, which
cannot be captured solely by product variety. We omit the firms that have missing
data. After applying these rules, we take a step further and identify the phar-
maceutical and medical device firms by analyzing the SICs of the firms. Firms’
respective SICs are obtained from the CompuStat database. Subsequently, the
number of pharmaceutical companies we determine is 36 and medical device firms
is 92. However, there are firms that are included in both the pharmaceutical SIC
and medical device SICs in the CompuStat database. We have separated these
firms into pharmaceutical or medical device via examining the products on their
web sites. We have followed these procedures in order to increase the sample size
of our study. Furthermore, we generate another dataset that combines pharma-
ceutical and medical device firms and contains 128 firms. From this dataset we
have omitted 2 outliers, which we think will effect the assumptions of regression.
We have identified outliers using STATA command “lvr2plot”, which plotted the
outliers of the data set. By removing 2 firms we are left with 126 firms that is 36
pharmaceutical firms and 90 medical device firms. This data set, also, has only
the firms with product variety greater than or equal to five. We use the combined
data as the master data set in our study. Tables 4.3, 4.4, 4.5 and 4.6 describe the
firms we have used and their respective SIC.
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Company SIC Firms
Type Codes
Pharmaceutical 2834 Teva Pharmaceutical Industries Ltd
Drug Firms Mylan Inc
(PDF) Glaxosmithkline PLC
Pfizer Inc
Watson Pharmaceuticals Inc.
Novartis AG
Perrigo Company
Par Pharmaceutical Companies Inc.
Merck and Co Inc.
Astrazeneca PLC
Eli Lilly and Company
Lannett Company Inc.
Allergan Inc.
Bristol-Myers Squibb Company
Taro Pharmaceutical Industries Ltd
Warner Chilcott Plc
Shire PLC
ProPhase Labs Inc
Cephalon Inc
Endo Pharmaceuticals Holdings Inc
Akorn Inc.
Salix Pharmaceuticals Ltd
Medicis Pharmaceutical Corp.
Cornerstone Therapeutics Inc.
Celgene Corp.
Columbia Laboratories Inc.
United Therapeutics Corp.
Amylin Pharmaceuticals Inc.
PDF 2836 Baxter International Inc.
Amgen Inc.
Gilead Sciences Inc.
PDF 2844 Avon Products Inc.
Colgate-Palmolive Company
L’Oreal S.A., Paris
CCA Industries Inc.
Estee Lauder Companies Inc.
Table 4.3: SIC Code Classification of Pharmaceutical Firms
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Company SIC Firms
Type Codes
Medical Device 2834 Roche Holding AG
Firms Abbott Laboratories
(MDF) Johnson and Johnson
Elan Corp PLC
Hospira Inc.
Derma Sciences Inc.
Rockwell Medical Technologies Inc.
MDF 2835 American Bio Medica Corp.
OraSure Technologies Inc.
Hemagen Diagnostics Inc.
Quidel Corp.
Corgenix Medical Corp.
Gen-Probe Inc.
Meridian Bioscience Inc.
Chembio Diagnostics Inc.
SeraCare Life Sciences Inc.
Trinity Biotech PLC
MDF 2836 Kinetic Concepts Inc.
MDF 3841 Boston Scientific Corp.
Becton, Dickinson and Company
NuVasive Inc.
Tornier NV
Merit Medical Systems Inc.
ICU Medical Inc.
Teleflex Inc.
Bard (C.R.) Inc.
Orthovita Inc.
AtriCure Inc.
LeMaitre Vascular Inc.
Mako Surgical Corp.
CareFusion Corp.
Rochester Medical Corp.
Cardica Inc.
Orthofix International NV
Atrion Corp.
Synergetics USA Inc.
Cardiovascular Systems Inc.
Retractable Technologies Inc.
Table 4.4: SIC Code Classification of Medical Device Firms
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Company SIC Firms
Type Codes
MDF 3842 Smith and Nephew PLC
Zimmer Holdings Inc.
Wright Medical Group Inc.
Exactech Inc.
Vascular Solutions Inc.
Edwards Lifesciences Corp.
Invacare Corp.
Stryker Corp.
Integra LifeSciences Holdings Corp.
Alphatec Holdings Inc.
Kensey Nash Corp.
Allied healthcare Products Inc.
Regeneration Technologies Inc.
Span-America Medical Systems Inc.
MDF 3843 Dentsply International Inc.
Sirona Dental Systems Inc.
Biolase Technology Inc.
MDF 3844 Hologic Inc.
Table 4.5: SIC Code Classification of Medical Device Firms Continued
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Company SIC Firms
Type Codes
MDF 3845 ArthroCare Corp.
St.Jude Medical Inc.
Resmed Inc.
Varian Medical Systems Inc.
Cynosure Inc.
Masimo Corp.
Conmed Corp.
Zoll Medical Corp.
Covidien Plc
Mindray Medical International Ltd.
Intuitive Surgical Inc.
NxStage Medical Inc.
Syneron Medical Ltd.
Given Imaging Ltd.
Palomar Medical Technologies Inc.
SonoSite Inc.
Spectranetics Corp.
Volcano Corp.
Cambridge Heart Inc.
Stereotaxis Inc.
Accuray Inc.
CAS Medical Systems Inc.
Trimedyne Inc.
IRIDEX Corp.
Utah Medical Products Inc.
Digirad Corp.
Natus Medical Inc.
Cutera Inc.
Dynatronics Corp.
Bovie Medical Corp.
Paradigm Medical Industries Inc.
Hansen Medical Inc.
Electromed Inc.
Fonar Corp.
Table 4.6: SIC Code Classification of Medical Device Firms Continued
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We combine the dataset of pharmaceutical drug companies and medical device
companies into a single dataset, which we used in our analysis. Hence, our final
test sample consists of 126 observations taken from year 2010. Then, we generat
hypothesis for test samples. In order to understand the hypotheses, we first
describe the setup and the notations of the problem and how we used the data
obtained from WRDS Compustat and FDA database in our calculations. Data
description is available Table 4.7.
Notation Description
ILi Inventory amount of firm i
COGSi Cost of goods sold of firm i
PVi Product Variety of firm i
STi Sales turnover ratio of firm i
Ai Total Assets of firm i
CAi Current Assets of firm i
Si Sales, net of markdowns in dollars for firm i ($ million)
GFAi Gross fixed asset of firm i
Ti Type of firm i
1: Pharmaceutical Drug Firm
0: Medical Device Firm
Table 4.7: Notations and Descriptions
To compare the effects of the variables we have used performance variables
described below:
Inventory Turnover ratio shows how many times a company’s inventory is sold
and replaced and is calculated by dividing inventory to cost of goods sold.
ITi =
COGSi
ILi
.
Gross Margin is the ratio of company’s total sales revenue minus cost of goods
sold, divided by the total sales revenue and it is expressed as a percentage. The
higher this percentage, the more company retains on each dollar of sales and is
represented as;
GMi =
Si − COGSi
Si
.
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Capital Intensity is the ratio of gross fixed assets to the total assets
CI i =
GFA
ILi +GFAi
.
Gross Fixed Assets is total assets minus the current assets.
GFAi = Ai − CAi.
Table 4.8 describes the statistics of our dataset. We have analyzed a total
of 126 firms. These firms include 36 pharmaceutical drug firms and 90 medical
device firms. Average inventory turnover of 126 firms is 2.78 with a standard
deviation of 2.07 and a median of 2.42. Average gross margin is approximately
0.63 having a standard deviation of 0.17 and a median of 0.64. Average capital
intensity is 0.74 with a standard deviation of 0.18 and a median of 0.79. Average
product variety is 70.15, has a deviation of 120.01 and a median of 26. Note that,
the standard deviations of each variable for each type of firm are presented in
brackets.
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Description Pharmaceutical Drug Medical Device Combined
Firms Firms
SIC 2834, 2836 2834, 2835, 2836
Codes 2844 3841, 3842, 3843
3844, 3845
Number of 36 90 126
Firms
Average Inventory Turnover 2.5366 2.8751 2.7784
Standard Deviation (1.3947) (2.2855) (2.0706)
Maximum 8.3488 16.4467 16.4467
Minimum 0.7404 0.5228 0.5228
Median 2.3157 2.5106 2.4153
Average Gross Margin 0.7134 0.5909 0.6259
Standard Deviation (0.1619) (0.1571) (0.1682)
Maximum 0.9307 0.8824 0.9308
Minimum 0.3672 0.1889 0.1889
Median 0.7597 0.6072 0.6374
Average Capital Intensity 0.8378 0.7039 0.7422
Standard Deviation (0.1519) (0.1815) (0.1833)
Maximum 0.9740 0.9657 0.9740
Minimum 0.2795 0.2362 0.2362
Median 0.8752 0.7585 0.7926
Product Variety 119.5833 50.3667 70.1429
Standard Deviation (177.6148) (80.2396) (120.0120)
Maximum 721 402 721
Minimum 5 5 5
Median 49 22.0 26.0
Table 4.8: Summary Statistics of the Dataset
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Chapter 5
Hypothesis
We have developed hypotheses to test the relations among inventory turnover,
gross margin, capital intensity and product variety using the combined data of
126 pharmaceutical and medical device manufacturing firms in their fiscal year
2010. Gaur et. al [4] have previously studied the correlation among inventory
turnover, gross margin, capital intensity and sales surprise for the period 1985-
2000. We test some of the hypothesis that are proposed by Gaur et al. [4] for our
dataset. Furthermore, we have developed hypothesis to understand the effect of
product variety on inventory turnover and inventory level.
5.1 Gross Margin
Hypothesis 1 Inventory turnover is negatively correlated with gross margin
To explain the hypothesis let us consider the classical newsboy model. News-
boy model allows us to determine the order quantity to satisfy demand during a
short period with stochastic demand and no replenishment opportunities. In the
classical newsboy setting, it can be proved that as gross margin increases, inven-
tory level increases, which implies a decrease in the inventory turnover. Thus, an
increase in the gross margin decreases the inventory turnover. Additionally, price
can be a factor affecting gross margin. As price of the products increase the gross
margin will increase. However, simply by taking into account the supply demand
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curve, the demand will fall due to increase in price; thus, decreasing inventory
turnover.
5.2 Capital Intensity
Hypothesis 2 Inventory turnover is positively correlated with capital intensity
Capital intensity is the amount of capital in relation to the factors of produc-
tion. Capital investments in information technologies, warehouse, supply chain
systems might improve the inventory management systems, hence, increasing the
inventory turnover. To prove this assertion, let us consider a depot-warehouse
system with independently identically distributed demand at the warehouses as
stated in the model by Eppen and Schrage [22]. Inserting a depot before the
warehouses will decrease the amount of inventory held at the warehouses [4].
This effect is called the joint ordering effect [23]. As the average inventory hold-
ing decreases, this will in turn increase the inventory turnover. Additionally, any
capital investment on information systems will allow better management of in-
ventory by decreasing lead times, effectively forecasting customer demand and
reducing order batch sizes.
5.3 Product Variety
Hypothesis 3 Inventory turnover is negatively correlated with product variety
Given that the total demand does not change, an increase in product variety
increases coefficient of variation, hence the inventory level. Coefficient of varia-
tion allows us to compare two or more different magnitudes of variation and is
represented by the ratio of standard deviation divided by its mean, (σ
µ
). There-
fore, the increase in inventory level, in return decreases the inventory turnover
ratio.
We can also explain the validity of the hypothesis using the concept risk
pooling effect. Eppen [23] indicates that risk pooling allows firms to manage un-
certainty, while driving costs down and increasing the profit level. Risk pooling,
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in products, is to decrease the number of variety in a product line. Lower product
variety through delayed differentiation helps increase inventory turnover. More-
over, lower variety will allow firms to forecast demand accurately. Kekre and
Srinivasan [9] point out that an increase in variety will increase inventory level.
However, the authors also state that, if the company can take advantage of in-
creasing product variety, while achieving a higher market share, total inventory
level will decrease. While the market share expansion may be the case for con-
sumer goods and industrial goods, we do not expect an increase in market share
for the health care industry. So, an increase in product variety will only increase
inventory level. By the formulae of inventory turnover, an increase in inventory
level would definetly bring forth a decrease inventory turnover. Therefore, our
hypothesis will hold.
Also, fewer number of product variety indicates less variability, lower σ
µ
, since
the aggregation effect becomes more significant, which in return allows for better
forecasts. As the number of products increase it gets more difficult to forecast
demand.
We use graphs, in order to have an initial understanding of the impact of
product variety on inventory turnover. First, we plot the histogram of logarithm
of inventory turnover and logarithm of product variety for medical device com-
panies in graphs 5.1 and 5.2. The heights of the bars drawn over the ln(IT ) and
ln(PV ) invervals indicate the frequency of the respective intervals. Notice that
the intervals have equal width, since the area of the bar is proportional to its
relative frequency. Figure 5.1 describes the frequency of ln(IT ) variable for 90
medical device firms. 1 is the most observed logarithm of iventory turnover value
for medical device companies. The latter histogram 5.2 shows the frequency of
logarithm of product variety for medical device companies. We observe that the
logarithm of product variety values tend to pile up between 2 and 3.
We plot similar histograms for 36 pharmaceutical companies. Histogram figure
5.3 plots the occurance rate of ln(IT ) for pharmaceutical companies. According to
the graph, ln(IT ) value around 1 has the highest occurance rate. Histogram figure
5.4 shows the frequency distribution of ln(PV ) for for pharmaceutical companies.
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Figure 5.1: Histogram of ln(IT) medical device companies
From this figure we observe that ln(PV ) values accumulate between 3 and 4.
We plot a scattered graph to show the relationship between IT and PV for
medical device companies, which is shown in figure 5.5. We also provide a fitted
curve. STATA estimates a single relationship between IT and PV for all obser-
vations and then plots the fitted values of IT and PV . In order to fit a line in
the scatter graph, we use the “lfitci” command of STATA [24], which draws a
fitted regression line for IT and PV values. Furthermore, we provide confidence
intervals to forecast the actual value of (IT |PV ) by using the “stdf” command
in STATA in figure 5.5. Even though there are some outliers in the dataset, the
fitted line in figure 5.5 shows that there is a vague negative relationship between
IT and PV . Using the similar graph plotting method as in the previous figure
we have draw the scattered plot graph, fitted the values of ln(IT ) and ln(PV )
and constructed the confidence bands for predicting the actual values of ln(IT )
and ln(PV ) in figure 5.6. We observe that as the logarithm of PV increases the
logarithm of IT tends to decrease. Additionally, note that the widths of the con-
fidence interval is large since the values gets further away from the mean of our
dataset. Although the relationship between inventory turnover and product vari-
ety is obscure in the graphs, both figures 5.5 and 5.6 weakly support hypothesis
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Figure 5.2: Histogram of ln(PV) for medical device companies
Figure 5.3: Histogram of ln(IT) for pharmaceutical companies
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Figure 5.4: Histogram of ln(PV) for pharmaceutical companies
3.
We have drawn scattered plot graphs of IT versus PV for pharmeceutical
companies in figure 5.7. When we analyze the scatter plots, we discover an
unclear relationship between IT and PV but the fitted curve shows a negative
relationship between the two variables. Moreover, over the range of the values,
the width of the interval changes as we go further from the mean value of PV .
This figure weakly supports hypothesis 3. Another graph we have plotted for
pharmaceutical companies is the scattered plot graph of ln(IT ) and ln(PV ),
which is displayed in figure 5.8. There does not exist a clear pattern in the
fitted regression line for ln(IT ) and ln(PV ) for pharmaceutical firms, hence,
no correlation between them. In order to understand the correlation between
product variety and inventory level we have developed hypothesis 4. Another
scattered plot figure we have plotted for medical device firms is figure 5.9. On
the y-axis we have ln(IT ) minus the estimate of ln(IT ) and on the x-axis we have
ln(PV ). We would have expected that in cases where ln(IT ) minus estimate of
ln(IT ) are positive PV has to be higher and in cases where it is negative, PV has
to be low. However, this clearly is not the case. We have constructed a similar
scattered graph for pharmaceutical companies displayed in figure 5.10. The fitted
37
Figure 5.5: IT versus PV for medical device companies
Figure 5.6: ln(IT) versus ln(PV) for medical device companies
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Figure 5.7: IT versus PV for pharmaceutical companies
Figure 5.8: ln(IT) versus ln(PV) for pharmaceutical companies
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Figure 5.9: Difference between ln(IT) and the estimate of ln(IT) vs ln(PV) for
medical device companies
regression line plotted using “lfitci” command of STATA, shows that there exist
no correlation between these two variables. It may be because product variety
influences inventory level and cost of goods sold simultaneously, the relationship
between product variety and inventory cannot be sought clearly using graphical
methods.
Hypothesis 4 Inventory level is positively correlated with product variety
Assuming that the demand is constant, an increase in product variety will
divide the same amount of demand to a larger number of products increasing the
variability, which in return increases the inventory level. Additionally, increase
in the variety results in an increase in the number of different inventory items
kept [25]. The relationship between inventory levels and product variety has been
studied by Ton and Raman [10]. The authors indicate that there is a trade-off
between product variety and the optimal level of inventory held at a specific store,
since variety would increase the inventory levels of the related store. A paper by
van Ryzin and Mahajan [11] argues that there is an implicit cost related with
having a large amount of product variety and this cost is mostly derived from the
level of inventory kept at the retailer’s stock. Kekre and Srinivasan [9] indicate
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Figure 5.10: Difference between ln(IT) and the estimate of ln(IT) vs ln(PV) for
pharmaceutical companies
that as product lines get broader a variety of finished goods inventory and safety
stock will be needed, which in return increase the inventory level. But the authors
note that having a broader product line will increase market share therefore,
reduce total level of inventory. We mainly state that, in health care industry,
broader product line would lead to an increase in cost of goods sold, which has
an indirect positive effect on inventory level. However, note that, product variety,
also, has a direct increasing effect on inventory level. This direct impact is due
to failure of taking advantage of risk pooling effect as product variety increases.
Furthermore, an increase in product variety will increase setup times, which in
return would increase total inventory level. We argue that an increase in cost of
goods sold due to an increase in product variety will be relatively lower than the
effect of an increase in product variety on inventory level. Leading to a conclusion
that inventory level is positively correlated with product variety.
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Chapter 6
Model Specifications and
Analysis
6.1 Regression Models
We use the following multiple linear regression and semi-log models to test hy-
pothesis 1 through 3.
Model 1
We begin by analyzing the following model;
ITi = α1 + α2GMi + α3CIi + α4PVi + α5Ti + i (6.1)
In the above equation (6.1), ITi is the dependent variable representing inventory
turnover of firm i, GMi is the gross margin of firm i, CIi is the capital intensity
of firm i, PVi is the product variety of firm i all calculated using the formulas
presented in Chapter 4. T indicates the type of the firm. It takes the value
of 1 if the firm is a pharmaceutical firm and 0 if the firm is a medical device
manufacturer. We initially assume that inventory turnover is linearly related to
gross margin, capital intensity, type of the firm and product variety of firm i. In
this multiple regression model, α1 is the value of the dependent variable when each
of the independent, explanatory variables takes the value zero and the remaining
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items α2, α3,α5 and α4 describe the dependence of inventory turnover on gross
margin (GM), capital intensity (CI) and product variety (PV ), respectively. The
sign of α’s indicate the relationship between inventory turnover and the related
exogenous variable.
The results of equation 6.1 are given in Tables 6.1 and 6.2:
Number of observations 126
F(4,121) 13.39
Prob > F 0.0000
R-Squared 0.3068
Adjusted R-Squared 0.2839
Root MSE 1.7522
Table 6.1: Results of multiple regression model 1
IT Coefficient Std.Err. t P> |t| [95 % Conf. Interval]
GM -7.654113 1.084114 -7.06 0.000 [-9.800403, -5.507824]
CI 3.838169 1.015568 3.78 0.000 [1.827584, 5.848754]
PV -0.0025566 0.0013834 -1.85 0.067 [-0.0052955, 0.0001823]
T 0.2620416 0.3816994 0.69 0.494 [-0.493633, 1.017716]
cons. 4.825068 0.752984 6.41 0.000 [3.334338, 6.315799]
Table 6.2: Results of multiple regression model 1
The explanatory variables can only explain about 30.68% of the variation in the
inventory turnover. More importantly, PV is not a significant variable, since its
p-value is greater than 0.05. Furthermore, T is, also, not a significant variable.
However, before jumping into any conclusions we have to test the model for the
assumptions of multiple regressions we have stated in Chapter 3. First, we use the
“vif” command, which stands for variance inflation factor, of STATA to test for
colinearity of the model. V IF measures how much the variance of the coefficient
of estimate is inflated by multicolinearity. V IF values greater than 10 may pose
some problems, since the variable is considered as a linear combination of other
independent variables. 1/V IF is the tolerance level and is used to check for the
degree of colinearity. The results of the multicolinearity test is displayed in Table
6.3. According to the results for model 1, the model passes the multicolinearity
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Figure 6.1: Histogram of residuals for model 1
test. Note that, even when a model shows extreme multicolinearity the estimates
are still the best linear unbiased estimators (BLUE).
Variable VIF 1/VIF
CI 1.41 0.708632
GM 1.35 0.738490
T 1.22 0.819546
PV 1.12 0.891061
Mean VIF 1.28
Table 6.3: Test for multicolinearity for model 1
We use histogram to asses the residuals visually using Figure 6.1. We use
STATA command “histogram res, normal” to draw a histogram and superimpose
a normal line on it. The graph shows that the errors are not normally distributed.
We further use the “swilk res” command of STATA to numerically test for
normality of the error terms. The null hypothesis is; data is normally distributed.
We reject the null hypothesis and conclude that the residuals are not normally
distributed. The results are given in Table 6.4.
To test for homoscedasticity we plot residuals against the fitted values. If the
model is well-fitted there should not exist any pattern between residuals and the
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Variable Obs W V z Prob > z
Residuals 126 0.73308 26.768 7.384 0.00000
Table 6.4: Shapiro-Wilk W test for normal data for model 1
Figure 6.2: Residuals against fitted values for model 1
predicted values. The figure is presented in 6.2. Note that we put a reference
line at y = 0. We observe that pattern of the data point is getting wider toward
the end, which is a sign of heteroscedasticity. We, also, test for heteroskedastic-
ity in the model using “hettest” command of STATA. The test gives Breusch-
Pagan/Cook-Weisberg test statistics for the model. The observed p-value is 0
therefore, we reject the null hypothesis that the variables are homoscedastic.
The detailed results of the test is provided in Table 6.5.
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Figure 6.3: Scatter plot graphs of Residuals vs GM for model 1
χ2(1) 105.21
Prob >χ2 0.0000
Table 6.5: Breusch-Pagan / Cook-Weisberg test for heteroskedasticity for model
1
Another assumption we test is the linearity assumption of the model. In order
to test this assumptions we draw scatter graphs, which plot residuals against the
independent variables. These graphs are shown in Figures 6.5, 6.3 and 6.4. The
figures do not indicate a strong departure from linearity. We conclude that the
model 1 cannot pass the multiple regression assumptions. Hence, cannot be used
as a proper model.
Model 2
Another multiple regression model we test is the following linear model;
ITi = α1 + α2GMi + α3CIi + α4 ln(PVi) + α5Ti + i (6.2)
We give the multiple regression results of equation (6.2) in Tables 6.6 and 6.7.
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Figure 6.4: Scatter plot graphs of Residuals vs CI for model 1
Figure 6.5: Scatter plot graphs of Residuals vs PV for model 1
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Number of observations 126
F(4,121) 13.42
Prob > F 0.0000
R-Squared 0.3073
Adjusted R-Squared 0.2844
Root MSE 1.7515
Table 6.6: Results of multiple regression model 2
IT Coefficient Std.Err. t P> |t| [95 % Conf. Interval]
GM -7.441569 1.084294 -6.86 0.000 [-9.588214, -5.294923]
CI 3.973327 1.031491 3.85 0.000 [1.931218, 6.015437]
ln(PV) -0.2740662 0.1461138 -1.88 0.063 [-0.563337, 0.0152045]
T 0.2210755 0.3777569 0.59 0.559 [-0.5267938, 0.9689449]
cons. 5.369552 0.790067 6.80 0.000 [3.805406, 6.933699]
Table 6.7: Results of multiple regression model 2
30.73% of the variation in inventory turnover can be explained by the explana-
tory variables in the model. Additionally, by analyzing our results we observe
that inventory turnover is negatively correlated with gross margin just as we
stated in Hypothesis 1. Moreover, capital intensity is positively correlated with
inventory turnover, just like in Hypothesis 2. Type of the firm and product va-
riety is negatively correlated wih inventory turnover. However, since the p-value
of ln(PV ) and T is greater than 0.05 they are not significant.
We test the regression assumptions for model 2. We start by testing multi-
colinearity shown in Table 6.8. Judging by the results, there does not exist a
variable that is a linear combination of other variables and the model passes the
multicolinearity test.
Variable VIF 1/VIF
CI 1.46 0.686353
GM 1.36 0.737633
T 1.20 0.836048
ln(PV) 1.19 0.839806
Mean VIF 1.30
Table 6.8: Test for multicolinearity for model 2
To test the normality assumptions we use various methods. First, we draw a
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Figure 6.6: Histogram of residuals for model 2
histogram displayed in Figure 6.6. The normal line on the histogram is skewed
and indicates non-normality. In order to statistically understand the normality
assumption, we use Shapiro-Wilk W test. Again, we observe that the p-value is
below 0.05 level. Thus, we reject the null hypothesis that the residual terms are
normally distributed. The results are presented in Table 6.9.
Variable Obs W V z Prob > z
Residuals 126 0.74148 25.925 7.312 0.00000
Table 6.9: Shapiro-Wilk W test for normal data for model 2
We plot residuals against fitted values to check for heteroscedasticity in Figure
6.7. As in model 1, by analyzing the graph’s pattern, we observe that toward
the end of the figure the pattern is widening. This is a sign of heteroscedasticity.
We further use the “hettest” command to make sure that the residuals are het-
eroscedastic. The results are displayed in Table 6.10. Since the p-value equals to
0, we reject the null hypothesis that the residuals are homoscedastic.
49
Figure 6.7: Residuals against fitted values for model 2
χ2(1) 112.65
Prob >χ2 0.0000
Table 6.10: Breusch-Pagan / Cook-Weisberg test for heteroskedasticity for model
2
Analyzing the linearity assumption is not so straightforward in multiple re-
gression models. We use scatter plots of GM , CI and ln(PV ) to analyze the
linearity assumption. The Figures are presented in 6.8, 6.9 and 6.10. The three
residuals versus the independent variables do not indicate a strong departure from
linearity even though there are some outliers.
Model 2 fails the normality test and hence is not a valid multiple regression
model. The failure of normality assumption may be due to fluctuations in in-
ventory turnover data. We take the logarithm of inventory turnover to eliminate
these fluctuations in the rest of the models.
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Figure 6.8: Scatter graph residual vs GM for model 2
Figure 6.9: Scatter graph residual vs CI for model 2
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Figure 6.10: Scatter graph residual vs ln(PV) for model 2
Model 3
Next, we analyze the following multiple regression model in which we have
taken the logarithm of inventory turnover;
ln(ITi) = α1 + α2GMi + α3CIi + α4 ln(PVi) + α5Ti + i (6.3)
The results of the multiple regression model are given in tables 6.11 and 6.12.
Number of observations 126
F(4,121) 19.58
Prob > F 0.0000
R-Squared 0.3929
Adjusted R-Squared 0.3729
Root MSE 0.44945
Table 6.11: Results of multiple regression model 3
Again we observe that the gross margin is negatively correlated with inventory
turnover. Furthermore, capital intensity is positively correlated with inventory
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ln(IT) Coefficient Std.Err. t P> |t| [95 % Conf. Interval]
GM -2.307173 0.2782342 -8.29 0.000 [-2.858011, -1.756335]
CI 1.241072 0.2646848 4.69 0.000 [0.7170587, 1.765086]
ln(PV) -0.0914869 0.0374934 -2.44 0.016 [-0.1657149, -0.0172588]
T 0.1219985 0.0969339 1.26 0.211 [-0.0699078, 0.3139048]
cons. 1.653766 0.2027344 8.16 0.000 [1.2524, 2.055132]
Table 6.12: Results of multiple regression model 3
turnover. The reasons behind it were explained fully in hypothesis 1 and hy-
pothesis 2. We have used a log specification for product variety and observe that
the logarithmic variable product variety is negatively correlated with inventory
turnover. We find out that the log-linear model can explain 39.29% of the total
variation in inventory turnover.
We need to test the regression assumptions for model 3. We start by checking
for multicolinearity, displayed in Table 6.13. The data indicates that there is
no multicolinearity because the variance of inflation factors are smaller than 10.
Thus, there is no strong correlation between predictor variables.
Variable VIF 1/VIF
CI 1.46 0.686353
GM 1.36 0.737633
T 1.20 0.836048
ln(PV) 1.19 0.839806
Mean VIF 1.30
Table 6.13: Test for multicolinearity for model 3
We continue checking the assumptions by analyzing whether the error terms
are normally distributed. The Histogram is shown in Figure 6.11. The histogram
shows that the error terms are normally distributed. Additionally, we use the
Shapiro-Wilk W test to confirm that the normality assumptions stands. Table
6.14 shows the results of the normality test. The p-value is greater than 0.05,
therefore, we do not reject the null hypothesis and conclude that the residuals
are normally distributed.
We test for homoscedasticity. First, we use graphical methods for detecting
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Figure 6.11: Histogram of residuals for model 3
homoscedasticity in Figure 6.12. We observe that the scatter plot is evenly dis-
tributed along the x-axis. Then, we use a non-graphical method, Breusch-Pagan
/ Cook-Weisberg method to test for heteroskedasticity. The details of the results
are displayed in Table 6.15. Prob >χ2(1) is greater than 0.05, hence, we do not
reject the null hypothesis. The data is homoscedastic meaning all residuals have
the same variance.
Variable Obs W V z Prob > z
Residuals 126 0.99363 0.639 -1.007 0.84299
Table 6.14: Shapiro-Wilk W test for normal data for model 3
χ2(1) 0.02
Prob >χ2 0.8839
Table 6.15: Breusch-Pagan / Cook-Weisberg test for heteroskedasticity for model
3
To test the linearity assumption we draw scatter plots of each variable against
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Figure 6.12: Residuals against fitted values for model 3
the residuals. The Figures are listed in 6.13, 6.14 and 6.15. There does not seem to
be a strong deviation from linearity, the model satisfies the linearity assumption.
Model 3 passes the assumptions of the regression model. We can use model 3 as
a legitimate model in our study.
Model 4
For the fourth multiple regression model, we drop variable T from model 3;
ln(ITi) = α1 + α2GMi + α3CIi + α4 ln(PVi) + i (6.4)
We have omitted type of the firm variable, T , since it did not produce signif-
icant effects in any of the multiple regression equations. The results are given in
Tables 6.16 and 6.17.
This model seems to be a better fit than the other models. Approximately
39% of the variation in ln(IT ) can be explained by the model and it supports
hypothesis 1, 2 and 3 and each variable is significant. The type of the firm,
indeed, has a minimal effect on R2.
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Figure 6.13: Scatter graph residual vs GM for model 3
Figure 6.14: Scatter graph residual vs CI for model 3
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Figure 6.15: Scatter graph residual vs ln(PV) for model 3
Number of observations 126
F(3,122) 25.46
Prob > F 0.0000
R-Squared 0.3850
Adjusted R-Squared 0.3699
Root MSE 0.45052
Table 6.16: Results of multiple regression model 4
But we need to check whether the model passes the assumptions of regressions.
We begin by addressing the multicolinearity issue. Figure 6.18 shows the results
of the V IF calculated. According to these results multicolinearity problem does
not exist.
We draw histogram of the error terms to test for normality displayed in Table
6.16. The figure shows that the error terms are normally distributed. We also use
a numerical method to check for normality assumption. Table 6.19 provides the
results of the normality test. From the results, we conclude that error terms are
normally distributed, since the p-value is greater than our critical value of 0.05.
To check the homoscedasticity of residuals we plot the residuals against the
fitted values. The resulting scatter plot is displayed in Figure 6.17. The scatter
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ln(IT) Coefficient Std.Err. t P> |t| [95 % Conf. Interval]
GM -2.23789 0.2733861 -8.19 0.000 [-2.779085, -1.696695]
CI 1.29564 0.2617338 4.95 0.000 [0.7775118, 1.813768]
ln(PV) -0.0850832 0.0372353 -2.29 0.024 [-0.1587943, -0.0113721]
cons. 1.582666 0.19517 8.11 0.000 [1.196308, 1.969025]
Table 6.17: Results of multiple regression model 4
Figure 6.16: Histogram of residuals for model 4
plot seems normal. Moreover, we use a numerical method to test homoscedas-
ticity. The results are given in Table 6.20. We do not reject the null hypothesis
that the variance of the residuals is homogeneous.
Variable VIF 1/VIF
CI 1.42 0.705277
GM 1.30 0.767683
ln(PV) 1.17 0.855562
Mean VIF 1.30
Table 6.18: Test for multicolinearity for model 4
We check linearity assumption using GM , CI and ln(PV ) in Figures 6.18, 6.19
58
Variable Obs W V z Prob > z
Residuals 126 0.99308 0.694 -0.821 0.79409
Table 6.19: Shapiro-Wilk W test for normal data for model 4
Figure 6.17: Residuals against fitted values for model 4
and 6.20.
The model passes the assumptions of regression. We observe that R2 value
has only changed 0.79%, meaning that type of the firm has an insignificant effect
on the equation.
Model 5
Last multiple regression we analyzed is;
ln(ITi) = α1 + α2GMi + α3CIi + i (6.5)
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Figure 6.18: Scatter graph residual vs GM for model 4
Figure 6.19: Scatter graph residual vs CI for model 4
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χ2(1) 0.08
Prob >χ2 0.7719
Table 6.20: Breusch-Pagan / Cook-Weisberg test for heteroskedasticity for model
4
Figure 6.20: Scatter graph residual vs ln(PV) for model 4
Number of observations 126
F(2,125) 34.39
Prob > F 0.0000
R-Squared 0.3587
Adjusted R-Squared 0.3482
Root MSE 0.45819
Table 6.21: Results of multiple regression model 5
ln(IT) Coefficient Std.Err. t P> |t| [95 % Conf. Interval]
GM -2.292538 0.2769718 -8.28 0.000 [-2.840787, -1.744289]
CI 1.117901 0.2541604 4.40 0.000 [0.6148057, 1.620995]
cons. 1.455274 0.1902203 7.65 0.000 [1.078745, 1.831804]
Table 6.22: Results of multiple regression model 5
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The model explains 35.87% of the variation on the dependent variable. Gross
margin is negatively correlated with the logarithm of inventory turnover, whereas
capital intensity is positively correlated. These results strongly support hypothe-
sis 1 and hypothesis 2. Both variables are statistically significant since the p-value
is smaller than our critical value of 0.05.
We use the same tests to check whether the model passes the multiple re-
gression assumptions. Results of the colinearity test is displayed in Table 6.23.
There does not exist a strong correlation between results, the model passes the
multicolinearity test.
We check whether the errors are normally distributed using a histogram and
a numerical test. The histogram is presented in Figure 6.21. The figure signals a
normality of residuals. Furthermore, we use the numerical test of Shapiro-Wilk
W given in Table 6.24. We observe that errors are normally distributed, since we
cannot reject the null hypothesis.
Then we examine the residuals versus the fitted values of IT to understand
if there is a heteroskedasticity problem. There does not exist an obvious pattern
that deviates from homoscedasticity in Figure 6.22. Moreover, we use Breusch-
Pagan / Cook-Weisberg test for heteroskedasticity. The results are shown in
Table 6.25. We do not reject the null hypothesis and conclude that all of the
residuals are from a distribution with the same variance.
Variable VIF 1/VIF
CI 1.29 0.773604
GM 1.29 0.773604
Mean VIF 1.29
Table 6.23: Test for multicolinearity for model 5
Variable Obs W V z Prob > z
Residuals 126 0.99175 0.827 -0.426 0.66506
Table 6.24: Shapiro-Wilk W test for normal data for model 5
62
Figure 6.21: Histogram of residuals for model 5
To test for linearity assumption we use scatter plots of residuals versus GM and
χ2(1) 0.85
Prob >χ2 0.3564
Table 6.25: Breusch-Pagan / Cook-Weisberg test for heteroskedasticity for model
5
T in Figures 6.23 and 6.24, respectively.
The absence of ln(PV ) changes the R2 value approximately 3%, which is a
significant change.
Therefore, we accept Model 4 as the best multiple regression model with an R2
value of 39%. Apart from validating Hypothesis 1 and Hypothesis 2, we conclude
that as product variety increases the logarithm of inventory turnover decreases,
which is stated in Hypothesis 3.
To confirm our findings we run a stepwise regression in the multiple regression
model using “sw regress” command of STATA. STATA uses forward selection,
which means that the model starts in an empty state with no variables and
tests the significance of each variable by adding the variable that improves the
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Figure 6.22: Residuals against fitted values for model 5
Figure 6.23: Scatter graph residual vs GM for model 5
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Figure 6.24: Scatter graph residual vs CI for model 5
model most. Stepwise regression model we use takes GM , CI, T and ln(PV ) as
explanatory variables and ln(IT ) as the dependent variable. If the p-value of the
explanatory variable is below 0.05 level the variable is added to the regression
model and model is re-fitted with the newly added explanatory variable. This
process goes on until no further variable can be added. In the stepwise regression
model we build first, gross margin is added. The p-value of gross margin is 0, thus
significant and added to the model. Then, the model fits CI in the regression,
which has a p-value of 0. Lastly, the model includes ln(PV ) that has a p-value of
0.0240 in to the regression model. Stepwise regression finds Model 4 as the best
multiple regression model, just as we predicted.
Our results reports three main findings in line with the 3 hypotheses. First,
gross margin is negatively correlated with inventory turnover (Hypothesis 1). Sec-
ond, capital intensity is positively correlated with inventory turnover (Hypothesis
2). These results are in line with Gaur et. al [4] paper. In Gaur et. al paper
66.7% of within firm variation and 99.7% of total variation can be explained
with the independent variables. Overall fit of their chosen model is statistically
significant with a p-value smaller than 0.0001. Moreover, log(GMsit), log(CIsit)
and log(SSsit) are statistically significant in their model. The chosen model in
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the paper finds segmentwise estimate of coefficients for log(GM) that range from
-0.153 to -0.571 and log(CI) coefficients that range from 0.106 to 1.085.
Our model explains approximately 39% of the variation in inventory turnover
and is significantly correlated with IT . Also, our model fit is statistically signifi-
cant with a p-value of 0. We have all of our explanatory variables, GM , CI and
ln(PV ) statistically significant. Note that GM and CI are highly statistically
significant with p-values equal to 0. Our model finds GM coefficient estimate of
-2.237 and a CI coefficient of 1.295. The reason that Gaur et. al model explains
more significant part of the total variation may be due to the fact that they have
larger sample size and use panel data instead of just a years data to explain the
total variation, whereas we only use the data of 2010.
6.2 Simultaneous Equations Models
In order to validate Hypothesis 4, we need to analyze the effect of product
variety on inventory level. We use simultaneous equations models to test the
effect of product variety on inventory level. We cannot use OLS to explain the
relationships, since product variety has a joint effect on inventory level and cost
of goods sold, creating an endogeneity problem. Also, because we are dealing
with a large sample analysis the least square estimator is not convenient. That
is E() = 0 and cov(x, ) = 0 may not hold true. This can make the least square
estimator biased and inconsistent. Hence, our model may have an endogeneity
problem. Therefore, we use methods of moment principle of estimation as an
alternative to the least square estimation. The usual assumptions of our linear
and log-linear multiple regression model methods of moment leads us to the least
square estimator. But when x is correlated with the error term, the method
of moment leads to instrumental variable estimation that is the two stage least
squares estimation, which works in large samples.
We use two stage least squares method to analyze simultaneous equations. We
apply the “ivregress 2SLS” command of STATA. The commands inputs are the
estimator, in our case the two stage least square estimator, depvar1, the depen-
dent variable for the model that has an endogenous regressors, varlist1, which are
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Figure 6.25: Direct effects of variables among each other
the exogenous variables in the model that has the endogenous regressors, depvar2
is the endogenous regressors and varlistiv that are the exogenous variables that
are believed to affect the endogenous regressors.
As we explained in Chapter 3, two stage least square method first estimates
the parameters of the reduced form equations to obtain the predicted values then
replaces the endogenous variables on the right hand side of the structural equation
by their predicted values and estimates the parameters of this equation by least
squares. We give the results for both of the estimations.
The hypothesized effects among GM , CI PV , COGS and IL are displayed
in Figure 6.25.
The rest of the chapter discusses the simultanoeus equations models and its
results.
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Model 1
The first regression model we test using the two stage least square estimation
model is;
ln(COGSi) = β0 + β1 ln(GMi) + β2 ln(CIi) + β3Ti + β4 ln(PVi) + νi
ln(ILi) = α0 + α1 ln(PVi) + α2 ln(GMi) + α3 ln(CIi) + α4 ̂ln(COGSi) + i
(6.6)
The instrumented variable is ln(COGS) and instruments are ln(PV ), ln(GM),
ln(CI) and T .
For the first stage of two stage least square estimation, R2 equals to 0.67 and
the overall F -statistic is 62.85, which has a p-value of 0. All of the estimated
coefficients are statistically significant, indicating that the exogenous variables
have an effect on the logarithm of inventory.
For the second stage of the estimation, R2 equals to 96.5%. Note that, in
the two stage least square estimation ln(CI) is negatively correlated with the
inventory level and ln(COGS), ln(PV ) and ln(GM) have positive correlations.
However, ln(PV ) and ln(CI) are not statisticaly significant. Other variables have
statistically significant coefficient estimates.
By using the estat endogenous command of STATA, we test endogeneity of
our model with the null hypothesis being tested is:
Ho: variables are exogenous.
The p-values for the endogeneity test of model 1 are more than 0.05 thus,
insignificant. Hence, we reject the null hypothesis that variables are exogenous.
Furthermore, we use the “estat overid” command to test for overidentifying
restrictions. The null hypothesis of the test is that instruments are uncorrelated
with the error term. Since there are as many regressors as there are instruments,
the model s just identified.
The detailed results of two stage least square estimation, endogeneity test and
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overidentification test of model 1 is given in Table 6.26.
Results for the first stage of 2SLS estimation
Number of observations 126
F(4,121) 62.85
Prob > F 0.0000
R-Squared 0.6751
Adjusted R-Squared 0.6643
Root MSE 1.3435
ln(COGS) Coefficient Std.Err. t P> |t| [95 % Conf. Interval]
ln(PV) 1.015724 0.1119107 9.08 0.000 [0.7941677, 1.237281]
ln(GM) -0.4030481 0.4427377 -0.91 0.364 [-1.279564, 0.473468]
ln(CI) 3.18577 0.4505428 7.07 0.000 [2.293801, 4.077738]
T 0.8994063 0.2852513 3.15 0.002 [0.3346761, 1.464136]
cons. 2.095058 0.5198044 4.03 0.000 [1.065968, 3.124148]
Results for the second stage of 2SLS estimation
Number of observations 126
Wald χ2(4) 2493.77
Prob > χ2 0.0000
R-Squared 0.9645
Root MSE 0.44237
ln(IL) Coefficient Std.Err. z P> |z| [95 % Conf. Interval]
ln(COGS) 0.8894393 0.1044282 8.52 0.000 [0.6847638, 1.094115]
ln(PV) 0.1815355 0.1174355 1.55 0.122 [-0.0486338, 0.4117048]
ln(GM) 1.144836 0.1440294 7.95 0.000 [0.8625432, 1.427128]
ln(CI) -0.2481405 0.3822645 -0.65 0.516 [-0.9973651, 0.5010842]
cons. -0.420395 0.2992105 -1.41 0.160 [-1.006837, 0.1660468]
Results of the endogeneity test
Durbin (score)χ2(1) 0.04579 (p = 0.8306)
Wu-Hausman F(1,120) .043625 (p = 0.8349)
Table 6.26: Results for simultaneous equations model 1
Model 2
The second regression model we tested is;
ln(COGSi) = β0 + β1ln(PVi) + β2ln(GMi) + β3 ln(CIi) + β4Ti + νi
ln(ILi) = α0 + α1 ln(GMi) + α2 ln(CIi) + α3 ̂ln(COGSi) + i
(6.7)
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The instrumented variable is ln(COGS) and instruments are ln(PV ), ln(GM),
ln(CI) and T . For the first part of the least square estimation the R2 equals to
0.675 and the overall F -statistic is 62.85, which has a p-value of 0. The logarithm
of gross margin is not statistically significant since the respective p-value is bigger
than 0.05. In the second stage of the estimation, we observe that the logarithm
of cost of goods sold and gross margin have positive correlation with inventory
level and they are statistically significant at 0.05 level. The estimation fits well
with an R2 of 96%.
The Durbin test uses an estimate of the error term’s variable by assuming
the variable being tested is exogenous. The Wu-Hausman test assumes that the
variable being tested is endogenous. By examining the p-values of Durbin and
Wu-Hausman statistics at 5 % test level we reject the null hypothesis and conclude
that the variables are endogeneous.
We apply the overidentification test for model 2. The test is not statistically
significant. Therefore, the regressors are overidentified.
Details of all the test results for model 2 are given in the Table 6.27.
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Results for the first stage of 2SLS estimation
Number of observations 126
F(4,121) 62.85
Prob > F 0.0000
R-Squared 0.6751
Adjusted R-Squared 0.6643
Root MSE 1.3435
ln(COGS) Coefficient Std.Err. z P> |z| [95 % Conf. Interval]
ln(GM) -0.4030481 0.4427377 -0.91 0.364 [-1.279564, 0.473468]
ln(CI) 3.18577 0.4505428 7.07 0.000 [2.293801, 4.077738]
ln(PV) 1.015724 0.1119107 9.08 0.000 [0.7941677, 1.237281]
T 0.8994063 0.2852513 3.15 0.002 [0.3346761, 1.464136]
cons. 2.095058 0.5198044 4.03 0.000 [1.065968, 3.124148]
Results for the second stage of 2SLS estimation
Number of observations 126
Wald χ2(3) 2139.40
Prob > χ2 0.0000
R-Squared 0.9587
Root MSE 0.47738
ln(IL) Coefficient Std.Err. z P> |z| [95 % Conf. Interval]
ln(COGS) 1.042907 0.034953 29.84 0.000 [0.9744, 1.111413]
ln(GM) 1.176303 0.1538664 7.64 0.000 [0.8747301, 1.477875]
ln(CI) -0.7474577 0.2206064 -3.39 0.001 [-1.179838, -0.315077]
cons. -0.711891 0.2506946 -2.84 0.005 [-1.203243, -0.2205386]
Results of the endogeneity test
Durbin (score)χ2(1) 8.05295 (p = 0.0045)
Wu-Hausman F(1,121) 8.26139 (p = 0.0048)
Results of the overidentification test
Sargan (score)χ2(1) 2.052 (p = 0.1520)
Basmann χ2(1) 2.00319 (p = 0.1570)
Table 6.27: Results of model 2
Model 3
The third regression model we test using the two stage least square estimation
model is;
ln(COGSi) = β0 + β1 ln(PVi) + β2 ln(CIi) + β3 ln(GMi) + β4Ti + νi
ln(ILi) = α0 + α1 ln(PVi) + α2 ln(CIi) + α3 ̂ln(COGSi) + i
(6.8)
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The instrumented variable is ln(COGS) and instruments are ln(GM), ln(CI)
and T . For the first stage of 2SLS of model 3, we observe an R2 value of 67.5% and
the F value is 62.85 with a p-value of 0. Furthermore, logarithm of gross margin
is negatively correlated with cost of goods sold, whereas logarithm of capital
intensity and product variety are positively correlated. Type of the company,
also, has a positive effect on cost of goods sold. The last stage of 2SLS gives
94.3% value of R2. A relatively high R2 value implies that there is no weak
instrument problem. Additionally, inventory level has a positive correlation with
logarithm of cost of goods sold, capital intensity and product variety.
We do not reject the null hypothesis that the variables are exogenous, since
the Durbin score and the Wu-Hausman test both has a p-value larger than the
critical value of 0.05.
We have also tested whether the instruments used are correlated with the
error term in our model by using the overidentification test. The results of the
overidentification test indicate that the instruments are correlated with the error
term. Hence we reject the null hypothesis and conclude that the instruments
used cannot pass the overidentification test. The detailed results are presented
in Table 6.28.
72
Results for the first stage of 2SLS estimation
Number of observations 126
F(4,121) 62.85
Prob > F 0.0000
R-Squared 0.6751
Adjusted R-Squared 0.6643
Root MSE 1.3435
ln(COGS) Coefficient Std.Err. z P> |z| [95 % Conf. Interval]
ln(PV) 1.015724 0.1119107 9.08 0.000 [0.7941677, 1.237281]
ln(CI) 3.18577 0.4505428 7.07 0.000 [2.293801, 4.077738]
ln(GM) -0.4030481 0.4427377 -0.91 0.364 [-1.279564, 0.473468]
T 0.8994063 0.2852513 3.15 0.002 [0.3346761, 1.464136]
cons. 2.095058 0.5198044 4.03 0.000 [1.065968, 3.124148]
Results for the second stage of 2SLS estimation
Number of observations 126
Wald χ2(4) 1515.88
Prob > χ2 0.0000
R-Squared 0.9431
Root MSE 0.56016
ln(IL) Coefficient Std.Err. z P> |z| [95 % Conf. Interval]
ln(COGS) 0.8028541 0.131512 6.10 0.000 [0.5450952, 1.060613]
ln(PV) 0.3134629 0.1472114 2.13 0.033 [0.0249339, 0.6019919]
ln(CI) 0.4601252 0.4707129 0.98 0.328 [-0.4624551, 1.382705]
cons. -0.7890017 0.3743007 -2.11 0.035 [-1.522618, -0.0553858]
Results of the endogeneity test
Durbin (score)χ2(1) 0.685509 (p = 0.4077)
Wu-Hausman F(1,121) .661908 (p = 0.4175)
Results of the overidentification test
Sargan (score)χ2(1) 39.4037 (p = 0.0000)
Basmann χ2(1) 55.0584 (p = 0.0000)
Table 6.28: Results of model 3
Model 4
The fourth regression model we test using the two stage least square estimation
model is;
ln(COGSi) = β0 + β1 ln(PVi) + β2 ln(GMi) + β3 ln(CIi) + β4Ti + νi
ln(ILi) = α0 + α1 ln(PVi) + α2 ln(GMi) + α3 ̂ln(COGSi) + i
(6.9)
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The instrumented variable is ln(COGS) and instruments are ln(PV ), ln(GM),
ln(CI) and T . For model 4, the R2 of the first stage is 67.5% and the F -value is
62.85 with 4 degrees of freedom. The related p-value for the F -statistics is 0. For
the first part of the estimation, logarithm of gross margin is negatively correlated
with the logarithm of cost of goods sold. However, the effect of gross margin
is not significant since the p-value is above the critical level. The logarithm of
product variety and capital intensity are positively correlated with cost of goods
sold. Also, type of the firm is positively correlated with cost of goods sold and
they are statistically significant.
The 2SLS results have an R2 value of 96.22%. Note that the coefficient of
logarithm of cost of goods sold, product variety and capital intensity are positive,
indicating that as the logarithm of inventory increases so do these variables.
Moreover, the p-values are statistically significant. The coefficient of product
variety is 0.25. This model strongly supports hypothesis 4.
The variables have passed the endogeneity test. The p-values of Durbin and
Wu-Hausman test are above the critical level of 0.05. Thus, we fail to reject the
null hypothesis that the variables are exogenous.
Furthermore, we use the estat overid command to test for overidentifying
restrictions because we have more instrumental variables than endogenous ex-
planatory variables. Since the p-value of the test is above 0.05 we do not reject
the null hypothesis that the instruments are uncorrelated with the error term.
The results are reported in Table 6.29.
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Results for the first stage of 2SLS estimation
Number of observations 126
F(4,121) 62.85
Prob > F 0.0000
R-Squared 0.6751
Adjusted R-Squared 0.6643
Root MSE 1.3435
ln(COGS) Coefficient Std.Err. z P> |z| [95 % Conf. Interval]
ln(PV) 1.015724 0.1119107 9.08 0.000 [0.7941677, 1.237281]
ln(GM) -0.4030481 0.4427377 -0.91 0.364 [-1.279564, 0.473468]
ln(CI) 3.18577 0.4505428 7.07 0.000 [2.293801, 4.077738]
T 0.8994063 0.2852513 3.15 0.002 [0.3346761, 1.464136]
cons. 2.095058 0.5198044 4.03 0.000 [1.065968, 3.124148]
Results for the second stage of 2SLS estimation
Number of observations 126
Wald χ2(3) 2343.94
Prob > χ2 0.0000
R-Squared 0.9622
Root MSE 0.45625
ln(IL) Coefficient Std.Err. z P> |z| [95 % Conf. Interval]
ln(COGS) 0.8268617 0.0414086 19.97 0.000 [0.7457023, 0.9080211]
ln(PV) 0.24595 0.0647736 3.80 0.000 [0.118996, 0.3729039]
ln(GM) 1.123042 0.1444569 7.77 0.000 [0.8399118, 1.406173]
cons. -0.2578974 0.1690383 -1.53 0.127 [-0.5892065, 0.0734117]
Results of the endogeneity test
Durbin (score)χ2(1) 2.87072 (p = 0.0902)
Wu-Hausman F(1,121) 2.82107 (p = 0.0956)
Results of the overidentification test
Sargan (score)χ2(1) = 0.396123 (p = 0.5291)
Basmann χ2(1) = 0.381603 (p = 0.5367)
Table 6.29: Results of simultaneous equation model 4
Model 5
The fifth regression model we test using the two stage least square estimation
model is;
ln(COGSi) = β0 + β1 ln(PVi) + β2GMi + β3CIi + β4Ti + νi
ln(ILi) = α0 + α1 ln(PVi) + α2GMi + α3CIi + α4 ̂ln(COGSi) + i
(6.10)
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The instrumented variable is ln(COGS) and instruments are ln(PV ), GM ,
CI and T . The reduced form of model 5 has a F -statistic value of 67.59, which
has a p-value of 0. These values suggest that our model has statistically significant
explanatory power with an R2 of 69%. Furthermore, capital intensity and the
logarithm of product variety have positive correlation with logarithm of cost of
goods sold. Type of the firm has, also a positive correlation with cost of goods
sold. However, the logarithm of gross margin is negatively correlated with cost of
goods sold, indicating as gross margin decreases as cost of goods sold increases.
But as the p-value points out gross margin is not a statistically significant variable.
The 2SLS result has a R2 value of 96.48%. Logarithm of product variety has a
coefficient equal to 0.22 but is not a statistically significant variable. The p-values
indicate that the estimated slopes of the inventory curve is significantly different
from zero.
According to the endogeneity test, we do not reject the null hypothesis that
the variables are exogenous since the p-values are less than the critical value of
0.05.
There are no overidentifying restrictions in the model. The details of the
results are displayed in 6.30.
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Results for the first stage of 2SLS estimation
Number of observations 126
F(4,121) 67.59
Prob > F 0.0000
R-Squared 0.6908
Adjusted R-Squared 0.6806
Root MSE 1.3106
ln(COGS) Coefficient Std.Err. z P> |z| [95 % Conf. Interval]
ln(PV) 0.9893609 0.1093316 9.05 0.000 [0.7729101, 1.205812]
GM -1.187859 0.8113376 -1.46 0.146 [-2.794116, 0.4183974]
CI 5.902216 0.7718275 7.65 0.000 [4.37418, 7.430252]
T 0.7964782 0.2826617 2.82 0.006 [0.2368748, 1.356082]
cons. -2.293615 0.5911784 -3.88 0.000 [-3.464009, -1.123221]
Results for the second stage of 2SLS estimation
Number of observations 126
Wald χ2(3) 2539.74
Prob > χ2 0.0000
R-Squared 0.9648
Root MSE 0.44063
ln(IL) Coefficient Std.Err. z P> |z| [95 % Conf. Interval]
ln(COGS) 0.8625345 0.1193152 7.23 0.000 [0.6286809, 1.096388]
ln(PV) 0.2200516 0.1283106 1.71 0.086 [-0.0314327, 0.4715358]
GM 2.182231 0.281417 7.75 0.000 [1.630663, 2.733798]
CI -0.4118744 0.7893893 -0.52 0.602 [-1.959049, 1.1353]
cons. -1.980095 0.380406 -5.21 0.000 [-2.725677, -1.234513]
Results of the endogeneity test
Durbin (score)χ2(1) 0.262674 (p = 0.6083)
Wu-Hausman F(1,120) 0.250689 (p = 0.6175)
Table 6.30: Results of simultaneous equation model 5
Model 6
The sixth regression model we test using the two stage least square estimation
model is
ln(COGSi) = β0 + β1 ln(PVi) + β2GMi + β3CIi + β4Ti + νi
ln(ILi) = α0 + α1GMi + α2CIi + α4 ̂ln(COGSi) + i
(6.11)
The instrumented variable is ln(COGS) and instruments are ln(PV ), GM ,
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CI and T . The first stage results of model 6 has a R2 value of 69% with an
F -value of 67.59 and a p-value of 0. Capital intensity, type of the firm and the
logarithm of product variety are positively correlated with the logarithm of cost
of goods sold and these variables are statistically significant. Yet, gross margin is
negatively correlated with cost of goods sold and is not statistically significant.
The two stage least square estimation has anR2 value of 95.97%. Gross margin
and logarithm of cost of goods sold have positive correlation with the logarithm
of inventory level. Capital intensity is negatively correlated with inventory level.
Cost of goods sold has a 105% additional influence on inventory level with a wide
confidence interval.
According to the endogeneity test, we reject the null hypothesis. DWH test
has values 0.0043 and 0.0045, respectively. Therefore, the variables are not ex-
ogenous.
Model passes the overidentification test, which means that chosen instruments
are valid instruments.
The details of the results can be examined in Table 6.31
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Results for the first stage of 2SLS estimation
Number of observations 126
F(4,121) 67.59
Prob > F 0.0000
R-Squared 0.6908
Adjusted R-Squared 0.6806
Root MSE 1.3106
ln(COGS) Coefficient Std.Err. z P> |z| [95 % Conf. Interval]
GM -1.187859 0.8113376 -1.46 0.146 [-2.794116, 0.4183974]
CI 5.902216 0.7718275 7.65 0.000 [4.37418, 7.430252]
ln(PV) 0.9893609 0.1093316 9.05 0.000 [0.7729101, 1.205812]
T 0.7964782 0.2826617 2.82 0.006 [0.2368748, 1.356082]
cons. -2.293615 0.5911784 -3.88 0.000 [-3.464009, -1.123221]
Results for the second stage of 2SLS estimation
Number of observations 126
Wald χ2(3) 2218.98
Prob > χ2 0.0000
R-Squared 0.9597
Root MSE 0.47113
ln(IL) Coefficient Std.Err. z P> |z| [95 % Conf. Interval]
ln(COGS) 1.058744 0.0362086 29.24 0.000 [0.9877765, 1.129712]
GM 2.337936 0.2848068 8.21 0.000 [1.779725, 2.896147]
CI -1.602815 0.4013527 -3.99 0.000 [-2.389452, -0.8161782]
cons. -1.412448 0.2004703 -7.05 0.000 [-1.805362, -1.019533]
Results of the endogeneity test
Durbin (score)χ2(1) 8.15508 (p = 0.0043)
Wu-Hausman F(1,121) 8.37342 (p = 0.0045)
Results of the overidentification test
Sargan (score)χ2(1) = 2.57271 (p = 0.1087)
Basmann χ2(1) = 2.52212 (p = 0.1123)
Table 6.31: Results of simultaneous equation model 6
Model 7
The seventh regression model we test using the two stage least square estima-
tion model is;
ln(COGSi) = β0 + β1 ln(PVi) + β2GMi + β3CIi + β4Ti + νi
ln(ILi) = α0 + α1 ln(PVi) + α2GMi + α3 ̂ln(COGSi) + i
(6.12)
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The instrumented variable is ln(COGS) and instruments are ln(PV ), GM ,
CI and T . Capital intensity, type of the firm and logarithm of product variety
are positively correlated with the logarithmic function of cost of goods sold. All
of the aforementioned variables are statistically significant variables. The fitted
values of capital intensity and logarithm of product variety, for the first stage,
are high having wide range of confidence intervals. Gross margin is negatively
correlated with the logarithm of cost of goods sold but it is not a statistically
significant variable since it has a p-value of 0.146.
The second stage of the estimation has an R2 of 96.15%. The logarithm
of inventory level is positively correlated with gross margin, cost of goods sold
and logarithm of product variety. The variables all have a p-value of 0, hence,
statistically significant.
We apply Durbin and Wu-Hausman method to test for endogeneity. The
results are significant, thus we reject the null hypothesis.
Furthermore, we use the estat overid command to test for overidentifying re-
strictions. The p-value of the overidentifying restrictions test is above our critical
level of 0.05. Hence, we conclude that the instruments we have used have passed
the test.
The results are displayed in 6.32
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Results for the first stage of 2SLS estimation
Number of observations 126
F(4,121) 67.59
Prob > F 0.0000
R-Squared 0.6908
Adjusted R-Squared 0.6806
Root MSE 1.3106
ln(COGS) Coefficient Std.Err. z P> |z| [95 % Conf. Interval]
ln(PV) 0.9893609 0.1093316 9.05 0.000 [0.7729101, 1.205812]
GM -1.187859 0.8113376 -1.46 0.146 [-2.794116, 0.4183974]
CI 5.902216 0.7718275 7.65 0.000 [4.37418, 7.430252]
T 0.7964782 0.2826617 2.82 0.006 [0.2368748, 1.356082]
cons. -2.293615 0.5911784 -3.88 0.000 [-3.464009, -1.123221]
Results for the second stage of 2SLS estimation
Number of observations 126
Wald χ2(3) 2321.67
Prob > χ2 0.0000
R-Squared 0.9615
Root MSE 0.46083
ln(IL) Coefficient Std.Err. z P> |z| [95 % Conf. Interval]
ln(COGS) 0.8036444 0.0404662 19.86 0.000 [0.7243321, 0.8829567]
ln(PV) 0.2789459 0.063812 4.37 0.000 [0.1538766, 0.4040151]
GM 2.119616 0.266219 7.96 0.000 [1.597836, 2.641396]
cons. -2.156251 0.1833181 -11.76 0.000 [-2.515548, -1.796955]
Results of the endogeneity test
Durbin (score)χ2(1) 5.92394 (p = 0.0149)
Wu-Hausman F(1,121) 5.96952 (p = 0.0160)
Results of the overidentification test
Sargan (score)χ2(1) = 0.248888 (p = 0.6179)
Basmann χ2(1) = 0.239485 (p = 0.6246)
Table 6.32: Results of simultaneous equations model 7
Model 8
The eighth regression model we test using the two stage least square estimation
model is;
ln(COGSi) = β0 + β1 ln(PVi) + β2CIi + β3GMi + β4Ti + νi
ln(ILi) = α0 + α1 ln(PVi) + α2CIi + α3 ̂ln(COGSi) + i (6.13)
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The instrumented variable is ln(COGS) and instruments are ln(PV ) GM , CI
and T . The results of the least square estimation of the first stage is similar to
the previous model.
The 2SLS results have an R2 value equal to 91.23%. The logarithm of inventoy
level is positively correlated with capital intensity, logarithm of cost of goods
sold and product variety. The p-values indicate that ln(PV ) and ln(COGS)
are significant, where as CI is not. Capital intensity has the biggest influence on
invetory level with a coefficient value of 2.20. More importantly, product variety’s
regression coefficient is 0.54, supporting hypothesis 4. However, we need to be
sure that the variables pass the endogeneity and overidentification tests.
The results of endogeneity test dictate that we should reject the null hypoth-
esis that the variables are exogenous. The instruments we used in the model are
not valid instruments. Since the p-values are 0.0153 and 0.0163, respectively.
Furthermore, we use the estat overid command to test for over identifying re-
strictions. The p-values of the test have both values 0. Therefore, overidentifying
restrictions are rejected.
Using CI as an independent variable in the ln(IL) equation rather than GM ,
used in model 8, has decreased the R2 value significantly. The detailed results of
the model are given in Table 6.33.
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Results for the first stage of 2SLS estimation
Number of observations 126
F(4,121) 67.59
Prob > F 0.0000
R-Squared 0.6908
Adjusted R-Squared 0.6806
Root MSE 1.3106
ln(COGS) Coefficient Std.Err. z P> |z| [95 % Conf. Interval]
ln(PV) 0.9893609 0.1093316 9.05 0.000 [0.7729101, 1.205812]
CI 5.902216 0.7718275 7.65 0.000 [4.37418, 7.430252]
GM -1.187859 0.8113376 -1.46 0.146 [-2.794116, 0.4183974]
T 0.7964782 0.2826617 2.82 0.006 [0.2368748, 1.356082]
cons. -2.293615 0.5911784 -3.88 0.000 [-3.464009, -1.123221]
Results for the second stage of 2SLS estimation
Number of observations 126
Wald χ2(3) 996.14
Prob > χ2 0.0000
R-Squared 0.9123
Root MSE 0.69519
ln(IL) Coefficient Std.Err. z P> |z| [95 % Conf. Interval]
ln(COGS) 0.5739998 0.1788589 3.21 0.001 [0.2234429, 0.9245568]
ln(PV) 0.5410516 0.1916143 2.82 0.005 [0.1654944, 0.9166087]
CI 2.198443 1.126524 1.95 0.051 [-0.0095039, 4.406389]
cons. -2.220834 0.5981745 -3.71 0.000 [-3.393235, -1.048434]
Results of the endogeneity test
Durbin (score)χ2(1) 5.88732 (p = 0.0153)
Wu-Hausman F(1,121) 5.93081 (p = 0.0163)
Results of the overidentification test
Sargan (score)χ2(1) = 24.1567 (p = 0.0000)
Basmann χ2(1) = 28.7005 (p = 0.0000)
Table 6.33: Results of simultaneous equations model 8
Model 9
The ninth regression model we test using the two stage least square estimation
model is;
ln(COGSi) = β0 + β1PVi + β2GMi + β3CIi + β4Ti + νi
ln(ILi) = α0 + α1PVi + α2GMi + α3CIi + α4 ̂ln(COGSi) + i
(6.14)
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The instrumented variable is ln(COGS) and instruments are PV , CI, GM
and T . First stage regression has an R2 value of approximately 61%. Product va-
riety is positively correlated with logarithm of cost of goods sold with a coefficient
of 0.007. Capital intensity, also, has a high coefficient with 6.67.
The 2SLS estimation has an R2 value of 96.04%. Additionally, gross margin,
product variety and logarithmic functions of cost of goods sold have a positive
effect on the logarithm of inventory level. Note that PV and CI are insignificant
in the model with a p-value of 0.07 and 0.93.
The test of endogeneity fails to reject the null hypothesis and we conclude
that the variables are exogenous. Hence, the chosen instruments are valid.
The model is not overidentified, thus, has no overidentifying restrictions.
The results are presented in Table 6.34
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Results for the first stage of 2SLS estimation
Number of observations 126
F(4,121) 47.46
Prob > F 0.0000
R-Squared 0.6107
Adjusted R-Squared 0.5979
Root MSE 1.4705
ln(COGS) Coefficient Std.Err. z P> |z| [95 % Conf. Interval]
PV 0.0073571 0.001161 6.34 0.000 [0.0050586, 0.0096557]
GM -0.4896769 0.9098216 -0.54 0.591 [-2.290909, 1.311555]
CI 6.671151 0.8522959 7.83 0.000 [4.983806, 8.358496]
T 0.7489908 0.3203338 2.34 0.021 [0.1148056, 1.383176]
cons. -0.3907765 0.6319272 -0.62 0.537 [-1.641843, 0.8602901]
Results for the second stage of 2SLS estimation
Number of observations 126
Wald χ2(3) 1989.69
Prob > χ2 0.0000
R-Squared 0.9604
Root MSE 0.4674
ln(IL) Coefficient Std.Err. z P> |z| [95 % Conf. Interval]
ln(COGS) 0.8348222 0.1359367 6.14 0.000 [0.5683912, 1.101253]
PV 0.0020303 0.0011313 1.79 0.073 [-0.000187, 0.0042476]
GM 2.330964 0.2825887 8.25 0.000 [1.7771, 2.884828]
CI -0.0845111 0.9875192 -0.09 0.932 [-2.020013, 1.850991]
cons. -1.561331 0.219445 -7.11 0.000 [-1.991435, -1.131227]
Results of the endogeneity test
Durbin (score)χ2(1) 0.766929 (p = 0.3812)
Wu-Hausman F(1,120) 0.734881 (p = 0.3930)
Table 6.34: Results of simultaneous equations model 9
Model 10
The tenth regression model we test using the two stage least square estimation
model is given as;
ln(COGSi) = β0 + β1PVi + β2GMi + β3CIi + β4Ti + νi
ln(ILi) = α0 + α1GMi + α2CIi + α3 ̂ln(COGSi) + i (6.15)
The instrumented variable is ln(COGS) and instruments are PV , GM , CI
and T .
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For the first stage of the least square estimation, we have an R2 of 61.07%
and an F value of 47.46 with a p-value of 0. Hence, the model is significant. The
logarithm of cost of goods is positively correlated with product variety, type of the
firm and capital intensity and negatively correlated with gross margin. However,
gross margin is not a statistically significant variable.
The 2SLS estimation has a R2 value of 0.9591, which means that we can
explain approximately 96% of the variation in the logarithm of inventory level.
When we analyze the estimation results, we observe that all but capital intensity
have a positive relation with the logarithm of inventory level. In the second stage
all of the variables are statistically significant.
We have applied the Durbin and Wu-Hausman test of endogeneity. The test
results have a p-value smaller than 0.05 hence, we reject the null hypothesis that
the variables used are exogenous.
Overidentifying restriction test is not rejected by Sargan χ2(1) and Basmann
χ2(1) tests, which yield a p-value of 0.0772 and 0.0795, respectively.
Details of the results are displayed in Table 6.35.
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Results for the first stage of 2SLS estimation
Number of observations 126
F(4,121) 47.46
Prob > F 0.0000
R-Squared 0.6107
Adjusted R-Squared 0.5979
Root MSE 1.4705
ln(COGS) Coefficient Std.Err. z P> |z| [95 % Conf. Interval]
GM -0.4896769 0.9098216 -0.54 0.591 [-2.290909, 1.311555]
CI 6.671151 0.8522959 7.83 0.000 [4.983806, 8.358496]
PV 0.0073571 0.001161 6.34 0.000 [0.0050586, 0.0096557]
T 0.7489908 0.3203338 2.34 0.021 [0.1148056, 1.383176]
cons. -0.3907765 0.6319272 -0.62 0.537 [-1.641843, 0.8602901]
Results for the second stage of 2SLS estimation
Number of observations 126
Wald χ2(3) 1926.11
Prob > χ2 0.0000
R-Squared 0.9591
Root MSE 0.47466
ln(IL) Coefficient Std.Err. z P> |z| [95 % Conf. Interval]
ln(COGS) 1.065955 0.0441713 24.13 0.000 [0.9793804, 1.152529]
GM 2.338464 0.2869504 8.15 0.000 [1.776052, 2.900877]
CI -1.663475 0.455423 -3.65 0.000 [-2.556088, -0.7708622]
cons. -1.403695 0.2042251 -6.87 0.000 [-1.803969, -1.003421]
Results of the endogeneity test
Durbin (score)χ2(1) 5.32278 (p = 0.0210)
Wu-Hausman F(1,121) 5.33701 (p = 0.0226)
Results of the overidentification test
Sargan (score)χ2(1) = 3.12289 (p = 0.0772)
Basmann χ2(1) = 3.07518 (p = 0.0795)
Table 6.35: Results of simultaneous equations model 10
Model 11
The eleventh regression model we test using the two stage least square esti-
mation model is;
ln(COGSi) = β0 + β1PVi + β2GMi + β3CIi + β4Ti + νi
ln(ILi) = α0 + α1PVi + α2GMi + α3 ̂ln(COGSi) + i
(6.16)
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The instrumented variable is ln(COGS) and instruments are ln(PV ), GM ,
CI and T .
Just like the previous model, the least square estimation has a R-squared
value equal to 0.6107.
The two stage estimation has a R2 of 95.94%. The logarithm of inventory level
is positively correlated with gross margin, product variety and the logarithm of
cost of goods sold. Each of the variables is statistically significant.
Since the p-values of the Durbin and Wu-Hausman test are less than our
chosen critical value of 0.05, we reject the null hypothesis. We conclude that the
variables are not exogenous.
Test statistics is χ2(1) distributed since the number of overidentifying restric-
tions equals to 1. Because p-values both equal to 0.93, which is greater than
0.05 (p > 0.05), we do not reject the null hypothesis that the overidentifying
restriction is valid.
Results are shown in Table 6.36.
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Results for the first stage of 2SLS estimation
Number of observations 126
F(4,121) 47.46
Prob > F 0.0000
R-Squared 0.6107
Adjusted R-Squared 0.5979
Root MSE 1.4705
ln(COGS) Coefficient Std.Err. z P> |z| [95 % Conf. Interval]
PV 0.0073571 0.001161 6.34 0.000 [0.0050586, 0.0096557]
GM -0.4896769 0.9098216 -0.54 0.591 [-2.290909, 1.311555]
CI 6.671151 0.8522959 7.83 0.000 [4.983806, 8.358496]
T 0.7489908 0.3203338 2.34 0.021 [0.1148056, 1.383176]
cons. -0.3907765 0.6319272 -0.62 0.537 [-1.641843, 0.8602901]
Results for the second stage of 2SLS estimation
Number of observations 126
Wald χ2(3) 1940.06
Prob > χ2 0.0000
R-Squared 0.9594
Root MSE 0.47334
ln(IL) Coefficient Std.Err. z P> |z| [95 % Conf. Interval]
ln(COGS) 0.8236232 0.0372671 22.10 0.000 [0.750581, 0.8966654]
PV 0.0021166 0.0005203 4.07 0.000 [0.0010968, 0.0031363]
GM 2.327524 0.2832693 8.22 0.000 [1.772326, 2.882721]
cons. -1.572136 0.1817723 -8.65 0.000 [-1.928403, -1.215868]
Results of the endogeneity test
Durbin (score)χ2(1) 7.70533 (p = 0.0055)
Wu-Hausman F(1,121) 7.88154 (p = 0.0058)
Results of the overidentification test
Sargan (score)χ2(1) = 0.007141 (p = 0.9327)
Basmann χ2(1) = 0.006858 (p = 0.9340)
Table 6.36: Results of simultaneous equations model 11
Model 12
The twelfth regression model we test using the two stage least square estima-
tion model is;
ln(COGSi) = β0 + β1PVi + β2CIi + β3GMi + β4Ti + νi
ln(ILi) = α0 + α1PVi + α2CIi + α3 ̂ln(COGSi) + i (6.17)
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The instrumented variable is ln(COGS) and instruments are PV , GM , CI
and T . The first stage of the least square estimation is similar to previous models
we have discussed.
The two stage least square estimation has a 93.71% R-squared value. The
explanatory variables are all significant and are positively correlated with the
dependent variable, logarithm of inventory level. Note that the coefficient of
determination of capital intensity has a high value. Therefore, has a strong rela-
tionship with the dependent variable. Estimated coefficient of cost of goods sold
is 0.815 indicating that ln(COGS) has a 82% effect on inventory level. However,
PV and CI are insignificant variables.
As in previous models we have implemented the DWH test. Because the
p-values are greater than the critical value of 0.05 we do not reject the null
hypothesis that the variables are exogenous.
The overidentification test results specify that we reject the null hypothesis
at 0.05 level. Hence, the chosen instruments PV , GM , CI and T are not valid.
The details are shown in Table 6.37.
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Results for the first stage of 2SLS estimation
Number of observations 126
F(4,121) 47.46
Prob > F 0.0000
R-Squared 0.6107
Adjusted R-Squared 0.5979
Root MSE 1.4705
ln(COGS) Coefficient Std.Err. z P> |z| [95 % Conf. Interval]
PV 0.0073571 0.001161 6.34 0.000 [0.0050586, 0.0096557]
CI 6.671151 0.8522959 7.83 0.000 [4.983806, 8.358496]
GM -0.4896769 0.9098216 -0.54 0.591 [-2.290909, 1.311555]
T 0.7489908 0.3203338 2.34 0.021 [0.1148056, 1.383176]
cons. -0.3907765 0.6319272 -0.62 0.537 [-1.641843, 0.8602901]
Results for the second stage of 2SLS estimation
Number of observations 126
Wald χ2(3) 1211.16
Prob > χ2 0.0000
R-Squared 0.9371
Root MSE 0.58874
ln(IL) Coefficient Std.Err. z P> |z| [95 % Conf. Interval]
ln(COGS) 0.8150675 0.1712006 4.76 0.000 [0.4795205, 1.150614]
PV 0.0021683 0.0014249 1.52 0.128 [-0.0006244, 0.004961]
CI 1.074237 1.231239 0.87 0.383 [-1.338947, 3.48742]
cons. -0.8735604 0.2556847 -3.42 0.001 [-1.374693, -0.3724275]
Results of the endogeneity test
Durbin (score)χ2(1) 0.653472 (p = 0.4189)
Wu-Hausman F(1,121) .630813 (p = 0.4286)
Results of the overidentification test
Sargan (score)χ2(1) = 42.8834 (p = 0.0000)
Basmann χ2(1) = 62.4292 (p = 0.0000)
Table 6.37: Results of simultaneous equations model 12
Model 13
In model 13, we removed GM and T variables from the ln(COGS) equation
in Model 8 (6.13) and the simultaneous equation becomes;
ln(COGSi) = β0 + β1 ln(PVi) + β2CIi + β2GMi + νi
ln(ILi) = α0 + α1 ln(PVi) + α2GMi + α3 ̂ln(COGSi) + i
(6.18)
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The first stage of the model yields an F -value of 82.76 with probability 0
and an R2 value of 67.05%. All exogeneous variables except gross margin is
statistically significant. Most effective variable on cost of goods sold is capital
intensity with a coefficient value of approximately 6.26.
Second stage diagnostics provide an R-squared value of 96.09%. All of the
variables in the second stage are significant and positively correlated with loga-
rithm of inventory level.
Judging by the p-values of the endogeneity test, we reject the null hypothesis
that variables are exogenous.
Since model 13 does not have any overidentified instruments we cannot per-
form the overidentification test. The details of the results are presented in 6.38.
Model 14
Model 14 is given as;
ln(COGSi) = β0 + β1 ln(PVi) + β2CIi + β3Ti + νi
ln(ILi) = α0 + α1 ln(PVi) + α2 ̂ln(COGSi) + i
(6.19)
In the first stage of the equation, we have ln(COGS) as the dependent en-
dogenous regressors and ln(PV ), CI and T as the exogenous variables. The
exogenous variables are all statistically significant with p-values less than 0.05.
The 2SLS results indicate an R2 value of 94.57%. All of the exogenous vari-
ables are positively correlated with the inventory level. Note that all but ln(PV )
is statistically significant. ln(PV ) has p-value approxiamtely equal to the critical
value of 0.05, thus, insignificant.
The endogeneity test results allow us to accept the null hypothesis since p-
values are highly significant. Therefore, our chosen instruments are exogenous
hence, uncorrelated with the error term.
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Results for the first stage of 2SLS estimation
Number of observations 126
F(3,122) 82.76
Prob > F 0.0000
R-Squared 0.6705
Adjusted R-Squared 0.6624
Root MSE 1.3474
ln(COGS) Coefficient Std.Err. z P> |z| [95 % Conf. Interval]
ln(PV) 1.031168 0.1113585 9.26 0.000 [0.8107226, 1.251613]
GM -0.73554 0.8176064 -0.90 0.370 [-2.354074, 0.8829936]
CI 6.258468 0.7827584 8.00 0.000 [4.708919, 7.808016]
cons. -2.757795 0.5836883 -4.72 0.000 [-3.913265, -1.602326]
Results for the second stage of 2SLS estimation
Number of observations 126
Wald χ2(3) 2243.59
Prob > χ2 0.0000
R-Squared 0.9609
Root MSE 0.46396
ln(IL) Coefficient Std.Err. z P> |z| [95 % Conf. Interval]
ln(COGS) 0.7967237 0.0430682 18.50 0.000 [0.7123116, 0.8811359]
ln(PV) 0.2879135 0.0667453 4.31 0.000 [0.1570952, 0.4187318]
GM 2.133824 0.2695548 7.92 0.000 [1.605507, 2.662142]
cons. -2.161588 0.1848758 -11.69 0.000 [-2.523938, -1.799238]
Results of the endogeneity test
Durbin (score)χ2(1) 5.94129 (p = 0.0148)
Wu-Hausman F(1,121) 5.98787 (p = 0.0158)
Table 6.38: Results of simultaneous equations model 13
By analyzing the overidentification test results we, again, observe that ln(PV ),
CI and T are valid instruments since p-values are bigger than the critical value
of 0.05.
The results of simultaneous equations model 14 is presented in Table 6.39.
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Results for the first stage of 2SLS estimation
Number of observations 126
F(3,122) 88.57
Prob > F 0.0000
R-Squared 0.6853
Adjusted R-Squared 0.6776
Root MSE 1.3167
ln(COGS) Coefficient Std.Err. z P> |z| [95 % Conf. Interval]
ln(PV) 0.9800595 0.1096572 8.94 0.000 [0.7629821, 1.197137]
CI 5.472716 0.7172414 7.63 0.000 [4.052865, 6.892567]
T 0.7146002 0.2783696 2.57 0.011 [0.1635398, 1.265661]
cons. -2.662872 0.5371785 -4.96 0.000 [-3.726271, -1.599474]
Results for the second stage of 2SLS estimation
Number of observations 126
Wald χ2(2) 1635.72
Prob > χ2 0.0000
R-Squared 0.9457
Root MSE 0.5470
ln(IL) Coefficient Std.Err. z P> |z| [95 % Conf. Interval]
ln(COGS) 0.9535979 0.0462302 20.63 0.000 [0.8629884, 1.044207]
ln(PV) 0.1492705 0.0758567 1.97 0.049 [0.0005941, 0.2979469]
cons. -1.129563 0.1527444 -7.40 0.000 [-1.428937, -0.83019]
Results of the endogeneity test
Durbin (score)χ2(1) 1.09567 (p = 0.2952)
Wu-Hausman F(1,122) 1.0702 (p = 0.3029)
Results of the overidentification test
Sargan (score)χ2(1) = 0.593063 (p = 0.4412)
Basmann χ2(1) = 0.576951 (p = 0.4475)
Table 6.39: Results of simultaneous equations model 14
Model 15
Model 15 is given as;
ln(COGSi) = β0 + β1 ln(PVi) + β2CIi + νi
ln(ILi) = α0 + α1 ln(PVi) + α2 ̂ln(COGSi) + i
(6.20)
By examining the results of Table 6.40 we observe that type of the firm does
not have any significant effect on the equation, since R2 changes approximately
94
1% from model 14 to model 15. The first stage still indicates a positive correlation
with the endogenous regressors, especially capital intensity. The two stage least
square estimation has a similar R2 value of 94.61%. All of the independent
variables are statistically significant.
We do not find any evidence of endogeneity, the results indicate that the
variables are exogenous hence, we do not reject the null hypothesis.
Since ln(COGS) is exactly identified. As we have previously mentioned, under
exact identification one cannot test instruments for exogeneity. Detailed results
of simultaneous equations model 15 can be find in Table 6.40.
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Results for the first stage of 2SLS estimation
Number of observations 126
F(2,123) 123.93
Prob > F 0.0000
R-Squared 0.6683
Adjusted R-Squared 0.6629
Root MSE 1.3463
ln(COGS) Coefficient Std.Err. z P> |z| [95 % Conf. Interval]
ln(PV) 1.022404 0.1108455 9.22 0.000 [0.802992, 1.241816]
CI 5.958079 0.7074194 8.42 0.000 [4.557786, 7.358373]
cons. -2.965009 0.5359039 -5.53 0.000 [-4.025798, -1.90422]
Results for the second stage of 2SLS estimation
Number of observations 126
Wald χ2(2) 1602.49
Prob > χ2 0.0000
R-Squared 0.9461
Root MSE 0.54527
ln(IL) Coefficient Std.Err. z P> |z| [95 % Conf. Interval]
ln(COGS) 0.9429849 0.0480876 19.61 0.000 [0.8487349, 1.037235]
ln(PV) 0.1637998 0.0779199 2.10 0.036 [0.0110796, 0.3165199]
cons. -1.12679 0.1523025 -7.40 0.000 [-1.425297, -0.8282828]
Results of the endogenity test
Durbin (score)χ2(1) .488634 (p = 0.4845)
Wu-Hausman F(1,122) .474964 (p = 0.4920)
Table 6.40: Results of model 15
Model 16
Model 16 is given as;
ln(COGSi) = β0 + β1 ln(PVi) + β2GMi + β3CIi + νi
ln(ILi) = α0 + α1 ln(PVi) + α2 ̂ln(COGSi) + i
(6.21)
In model 16, we add both gross margin and capital intensity to the cost of
goods sold equation to analyze the joint effect of the variables. In the first stage
of equation (6.21) the R2 value is 67.05% same as the previous model. In this
model, gross margin is still negatively correlated with cost of goods sold and
statistically insignificant. In the second stage, the R2 value is 94.64% and all of
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the variables are statistically significant. Product variety is positively correlated
with level of inventory.
Just like in the previous simultaneous equations model, this model, also, can-
not pass the endogeneity test and overidentification test.
The detailed results are given in Table 6.41
Results for the first stage of 2SLS estimation
Number of observations 126
F(3,122) 82.76
Prob > F 0.0000
R-Squared 0.6705
Adjusted R-Squared 0.6624
Root MSE 1.3474
ln(COGS) Coefficient Std.Err. z P> |z| [95 % Conf. Interval]
ln(PV) 1.031168 0.1113585 9.26 0.000 [0.8107226, 1.251613]
GM -0.73554 0.8176064 -0.90 0.370 [-2.354074, 0.8829936]
CI 6.258468 0.7827584 8.00 0.000 [4.708919, 7.808016]
cons. -2.757795 0.5836883 -4.72 0.000 [-3.913265, -1.602326]
Results for the second stage of 2SLS estimation
Number of observations 126
Wald χ2(2) 1588.72
Prob > χ2 0.0000
R-Squared 0.9464
Root MSE 0.5436
ln(IL) Coefficient Std.Err. z P> |z| [95 % Conf. Interval]
ln(COGS) 0.9085564 0.0476687 19.06 0.000 [0.8151274, 1.001985]
ln(PV) 0.2109328 0.0773673 2.73 0.006 [0.0592955, 0.36257]
cons. -1.117793 0.1518301 -7.36 0.000 [-1.415375, -0.8202118]
Results of the endogenity test
Durbin (score)χ2(1) 0.041955 (p = 0.8377)
Wu-Hausman F(1,122) 0.040636 (p = 0.8406)
Results of the overidentification test
Sargan (score)χ2(1) 45.6489 (p = 0.0000)
Basmann χ2(1) 69.3104 (p = 0.0000)
Table 6.41: Results of simultaneous equations model 16
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Model 17
Simultaneous equations model 17 is written as;
ln(COGSi) = β0 + β1 ln(PVi) + β2GMi + νi
ln(ILi) = α0 + α1 ln(PVi) + α2 ̂ln(COGSi) + i
(6.22)
In the first stage, the value of R2 we obtain is 49.79%, which is infact rela-
tively low compared to other simultaneous equations models. Gross margin and
logarithm of product variety is positively correlated with cost of goods sold and
they are significant.
In the second stage, R2 value, again, is relatively low compared to other models
with a value of 51.82%. ln(COGS) is positively correlated with the inventory level
,whereas ln(PV ) is negatively correlated but we observe that the effect of ln(PV )
is insignificant.
We have applied the DWH statistics in order to test for endogeneity. The test
leads to strong rejection of the null hypothesis that the instrumented variable is
exogenous.
Since there are as many instruments as regressors, the model is just identified.
The detailed results are given in Table 6.42.
98
Results for the first stage of 2SLS estimation
Number of observations 126
F(2,123) 60.98
Prob > F 0.0000
R-Squared 0.4979
Adjusted R-Squared 0.4897
Root MSE 1.6565
ln(COGS) Coefficient Std.Err. z P> |z| [95 % Conf. Interval]
ln(PV) 1.295774 0.130726 9.91 0.000 [1.03701, 1.554538]
GM 2.053007 0.9091769 2.26 0.026 [0.253347, 3.852667]
cons. -0.7710629 0.6493506 -1.19 0.237 [-2.056413, 0.5142869]
Results for the second stage of 2SLS estimation
Number of observations 126
Wald χ2(2) 154.13
Prob > χ2 0.0000
R-Squared 0.5182
Root MSE 1.6296
ln(IL) Coefficient Std.Err. z P> |z| [95 % Conf. Interval]
ln(COGS) 1.836089 0.4356451 4.21 0.000 [0.9822403, 2.689938]
ln(PV) -1.058869 0.6092747 -1.74 0.082 [-2.253025, 0.1352878]
cons. -1.360172 0.4676852 -2.91 0.004 [-2.276818, -0.4435255]
Results of the endogenity test
Durbin (score)χ2(1) 41.7438 (p = 0.0000)
Wu-Hausman F(1,122) 60.4436 (p = 0.0000)
Table 6.42: Results of simultaneous equations model 17
Tables 6.43 and 6.44 summarizes the results of the simultaneous equation
models we have tested using two stage least squares. We identify the significance
of each variable using two stage least squares. We display the dependent variable’s
p-value along with the p-values of each independent variable for every model in
Tables 6.43 and 6.44. Note that, a p-value smaller than 0.05 indicates that the
exogenous variable used in the model is a statistically significant variable for
that equation. As we have previously mentioned, we apply DWH test, to check
whether the related model has an endogeneity bias and overidentification test in
order to understand whether the model uses instruments that are valid. Note that,
“N/A” in an overidentification test means that the SEM is just identified. That
is number of endogenous variables equal to number of instrumental variables.
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When we interpret our findings we observe that Model 4 is the best model
among the 17 simultaneous equations models. It has an R2 value of 96% and
it passes the overidentification test and the endogeneity test. The coefficients of
Model 4 are all significantly different from zero with p-values of 0, thus, highly
statistictically significant. ln(COGS), ln(PV ) and ln(GM) are positively corre-
lated with ln(IL). It follows that the endogeneous variables are not correlated
with the error term, so the simultaneous equations model passes the DWH test.
Moreover, Model 4 passes the test for instrument validity, meaning that instru-
ments are exogenous. Our estimation results show that Model 4 has positive
correlation between inventory level and product variety, hence, supports Hypoth-
esis 4. Furthermore, Model 4 supports the relationships in Figure 6.25.
Unlike Kekre and Srinivasan’s [9] findings, our results of simultaneous equa-
tions models indicate that health care firms can increase product variety only at
the expense of increasing inventory level. Kekre and Srinivasan, also, point out
that total inventory would increase. However, the authors indicated that product
variety will have an impact on firm’s market share, thus, reducing the level of
inventory. In model 4, the first equation indicates that there is a positive corre-
lation between product variety and cost of goods sold, which indirectly indulges
an increase in inventory level. However, the increase in inventory cannot only
be explained by the indirect impact of cost of goods sold. Product variety has
a direct positive correlation with inventory level. This may be due to increased
setup times in the product line and other risk pooling. We manage to capture
exactly this effect in Model 4. The increase in inventory level, due to an increase
in product variety, has relatively a larger effect than its impact on cost of goods
sold.
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Chapter 7
Conclusion
In the thesis, we study the effect of gross margin, capital intensity and product
variety on inventory turnover. Moreover, we analyze the relationship between
product variety and inventory level. The analysis are done using empirical data
obtained from Wharton Research Data Services. The dataset contains a total
of 126 firms, which consist of 36 pharmaceutical and 90 medical device firms for
the fiscal year 2010. We test two hypotheses of Gaur et al. [4] on this dataset,
namely the effect of capital intensity to inventory turnover and the effect of gross
margin to inventory turnover. However, we extend Gaur et al. [4] study and
incorporate product variety’s effect into the models, as suggested by the authors.
We use multiple regression models and simultaneous equations models to test
the hypotheses. In order to test hypotheses 1, 2 and 3 we benefit from multiple
regression models, to test hypothesis 4 we use the simultaneous equation models.
Our primary interest is in the effect of product variety to inventory turnover and
inventory levels.
The first multiple regression model uses GM , CI, PV and T to identify
the independent effects on the dependent variable, inventory turnover. Multiple
regression Model 2 analyzes the effect of logarithm of product variety to inven-
tory turnover. Model 3 incorporates the effect of GM , CI, ln(PV ) and T to
ln(IT ). We observe that, by taking the logarithm of inventory turnover the R2
has increased significantly. In multiple regression model 4 we have eliminated the
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independent variable T , since we do not think that type of a firm has a major ef-
fect to ln(IT ). The R2 value drops slightly, just as we have predicted. Moreover,
stepwise regression confirms that Model 4 is the best multiple regression model
that can be built given the variables.
The last multiple regression model eliminates ln(PV ) from Model 4. We
observe that R2 has dropped by 3%. We conclude that ln(PV ) has a significant
effect on inventory turnover. Multiple regression Model 4 supports Hyptohesis
3 with an R2 of approximately 39%. Therefore, we choose multiple regression
model 4 as the best multiple regression model.
We test Hypothesis 4 using simultaneous equations models because product
variety has an influence both on inventory level and cost of goods sold, which
may lead to an endogeneity problem. We construct a rich variety of simultane-
ous equation models to understand the correlation between product variety and
inventory level. We apply instrumental variable estimator to solve simultane-
ous equations. More specifically, we use two stage least squares interpretation of
the instrumental variables. Furthermore, we test for endogeneity bias by using
Durbin-Wu-Hausman test and test for overidentifying restrictions using Sargan
and Basmann tests.
Simultaneous equations model 4 stands apart from the rest of the models. The
model has an R2 value of 96.22%, which means that approximately 96.22% of the
variation can be explained by the variables used. The two stage least square has
all the variables statistically significant and it passes the overidentification and
the endogeneity tests.
Kekre and Srinivasan [9] indicate that as product variety increases it produces
an increase in market share. Simultaneously, an increase in product variety in-
creases inventory level. However, the authors indicate that the firm will achieve
higher market share due to higher product variety, the inventory level would be
lower, thus, an increase in product variety will result in a reduction on the total
inventory level. However, our study shows that in health care industry this would
not be the case. We find that product variety triggers an increase in inventory
level. We argue that, in health care industry, an increase in product line will
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increase cost of goods sold and cost of goods sold will have an indirect effect on
inventory level. But from Model 4, we know that product variety has a direct
positive correlation with inventory level and this effect is bigger than the effect
of product variety on cost of goods sold. Therefore, a company with a boarder
product line as compared to a company with lower product line will on the aver-
age have more inventory held. Remember that inventory turnover is the ratio of
cost of goods sold divided by the inventory level. As inventory level increases the
inventory turnover ratio declines. Hence, an increase in product variety decreases
inventory turnover, which was stated in Hypothesis 3.
In our multiple regression analysis, Model 4 properly explains the mechan-
ics between product variety and inventory turnover. That is; as product variety
increases inventory turnover decreases. Furthermore, we have confirmed the hy-
potheses of Gaur et. al [4] that gross margin is negatively correlated with inven-
tory turnover (Hypothesis 1) and capital intensity is positively correlated with
inventory turnover (Hypothesis 2). We have shown that these hypotheses, also,
stand in the health care industry. Simultaneous equations model 4 explains the
dynamic between product variety and inventory level. Unlike Kekre and Srini-
vasan’s [9] paper, we find that as product variety increases so does inventory level.
Kekre and Srinivasan use self-reported data, which causes bias in the estimates
of the explanatory variables in the OLS estimation. Additionally, the product
variety data, obtained from PIMS database, is subjective in nature, whereas we
use real product variety data obtained from FDA. Moreover, the authors have
performed their analysis on four subgroupings, this causes heterogeneity problem
in their data. We manage to focus on a single industry so heterogeneity problem
does not exist in our dataset.
We should emphasize that product variety’s effect on inventory level strongly
depends on the industry analyzed. Although our results only cover the health
care sector, the tests can be used over wide range of industries and applications.
However, in other industries measuring product variety may not be easy. Detailed
analysis should be made of the effect of product variety in different sectors to cap-
ture the magnitude of its effect to inventory level and cost of goods sold. Other
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limitations of this study are that, it does not incorporate operational characteris-
tics such as price and length of product life cycle. Moreover, one can investigate
the effect of product variety on a panel data to clearly see the effects of product
variety.
106
Bibliography
[1] Standard&Poor’s, Industry Surveys Healthcare: Pharmaceuticals. Standard
& Poor’s, 2010.
[2] “Wharton Research Data Services. (2011),” University of Pennsylvania, Re-
trieved on August 2011.
[3] V. Gaur, S. Kesavan, and A. Raman, “Do inventory and gross margin data
improve sales forecasts for U.S. public retailers?,” Management Science,
vol. 56, no. 9, pp. 1519–1533, 2010.
[4] V. Gaur, M. L. Fisher, and A. Raman, “An econometric analysis of inventory
turnover performance in retail services,” Management Science, vol. 51, no. 2,
pp. 181–194, 2005.
[5] S. Rajagopalan and A. Malhotra, “Have U.S. manufacturing inventories re-
ally decreased? An empirical study,” Manufacturing & Service Operations
Management, vol. 3, no. 1, pp. 14–24, 2001.
[6] G. P. Cachon and M. Olivares, “Drivers of finished goods-inventory in the
U.S. automobile industry,” Management Science, vol. 56, no. 1, pp. 202–216,
2010.
[7] S. Roumiantsev and S. Netessine, “What can be learned from classical in-
ventory models: a cross-industry exploratory investigation,” Manufacturing
and Service Operations Management, vol. 9, no. 4, pp. 409–429, 2007.
107
[8] G. P. Cachon, T. Randall, and G. M. Schmidt, “In search of the bullwhip
effect,” Manufacturing & Service Operations Management, vol. 9, no. 4,
pp. 457–479, 2007.
[9] S. Kekre and K. Srinivasan, “Broader product line: A necessity to achieve
success?,” Management Science, vol. 36, no. 10, pp. 1216–1231, 1990.
[10] Z. Ton and A. Raman, “The effect of product variety and inventory lev-
els on retail store sales: A longitudinal study,” Production and Operations
Management Society, vol. 19, no. 5, pp. 546–560, 2010.
[11] G. van Ryzin and S. Mahajan, “On the relationship between inventory costs
and variety benefits in retail assortments,” Management Science, vol. 45,
no. 11, pp. 1496–1509, 1999.
[12] H. P. Marvel and J. Peck, “Inventory turnover and product variety,” Journal
of Law and Economics, vol. 51, no. 3, pp. 461–478, 2008.
[13] A. Balakrishnan, M. S. Pangburn, and E. Stavrulaki, “Stack them high, let
’em fly: Lot-sizing policies when inventories stimulate demand,” Manage-
ment Science, vol. 50, no. 5, pp. 630–644, 2004.
[14] G. P. Cachon, “Managing supply chain demand variability with scheduled
ordering policies,” Management Science, vol. 45, no. 6, pp. 843–856, 1999.
[15] StataCorp.2009, Stata Statistical Software: Release 11. College Station, TX:
StataCorp LP.
[16] W. H. Greene, Econometric Analysis. Prentice Hall, 2007.
[17] R. C. Hill, Undergraduate Econometrics. John Wiley & Sons Inc., 2001.
[18] T. Yamano, “Lecture notes on advanced econometrics,” Updated on October
2009.
[19] J. Durbin, “Errors in variables,” Revue de l’Institut International de Statis-
tique/Review of the International Statistical Institute, vol. 22, no. 1/3,
pp. 23–32, 1954.
108
[20] D. Wu, “Alternative tests of independence between stochastic regressors and
disturbances,” Econometrica, vol. 41, no. 4, pp. 733–750, 1973.
[21] J. A. Hausman, “Specification tests in econometrics,” Econometrica, vol. 46,
no. 6, pp. 1251–1271, 1978.
[22] G. D. Eppen and L. Schrage, “Centralized ordering policies in a multi-
warehouse system with lead times and random demand,” TIMS Studies in
Management Sciences, vol. 16, pp. 51–67, 1981.
[23] G. D. Eppen, “Effects of centralization on expected costs in a multi-location
newsboy problem,” Management Science, vol. 25, no. 5, pp. 498–501, 1979.
[24] A. C. Cameron and P. K. Trivedi, Microeconometrics Using Stata. College
Station, TX: StataCorp LP, 2009.
[25] S. Benjaafar, J. S. Kim, and N. Vishwanadham, “On the effect of product
variety in production - inventory systems,” Annals of Operations Research,
vol. 126, no. 1-4, pp. 71–101, 2004.
109
Appendix A
Data
110
Firm GM CI PV COGS IL
Teva Pharmaceutical 0.6275 0.8710 721 6,004 3,866
Industries Ltd
Mylan Inc 0.4863 0.8654 686 2,799.837 1,240.271
Roche Holding AG 0.7841 0.8705 402 11,327.784 5,306.863
Glaxosmithkline PLC 0.8018 0.8722 395 8,813.459 5,905.910
Baxter International Inc 0.5629 0.8003 377 5,707.000 2,371.000
Boston Scientific Corp 0.6884 0.9539 368 2,432.000 894.000
Smith & Nephew PLC 0.8082 0.7364 359 760.000 923.000
Abbott Laboratories 0.6763 0.9209 337 11,382.887 3,188.734
Pfizer Inc 0.8167 0.9412 317 12,423.000 8,405.000
Watson Pharmaceuticals Inc. 0.4768 0.8646 271 1,866.300 631.000
Johnson & Johnson 0.7426 0.9118 255 15,853.000 5,378.000
Novartis AG 0.7707 0.9407 243 11,609.000 6,093.000
Zimmer Holdings Inc. 0.8270 0.8420 218 730.000 936.400
Wright Medical 0.7632 0.6077 169 122.897 166.339
Group Inc
Perrigo Co 0.3672 0.7922 148 1,435.817 448.871
Par Pharmaceutical 0.3994 0.8083 131 605.954 72.580
Companies Inc
Becton, Dickinson and Co 0.5774 0.8179 113 3,115.201 1,145.337
ArthroCare Corp 0.7393 0.8489 105 92.651 34.087
Merck & Co Inc. 0.8941 0.9289 96 4,868.000 5,868.000
DENTSPLY 0.5397 0.8629 93 1,022.302 308.738
International Inc.
Astrazeneca PLC 0.8717 0.9485 89 4,359.000 1,682.000
Eli Lilly and Co 0.8600 0.8652 86 3,231.400 2,517.700
Exactech Inc. 0.6724 0.6356 86 62.405 61.602
St. Jude 0.7813 0.8944 86 1,129.423 667.545
Medical Inc.
Table A.1: Data
111
Firm GM CI PV COGS IL
Varian Medical 0.4557 0.6384 70 1,282.650 363.933
Systems Inc
Vascular Solutions Inc. 0.6821 0.7020 69 24.939 12.601
Cynosure Inc. 0.6321 0.5325 66 30.088 18.684
Lannett Co Inc. 0.3693 0.7327 66 78.951 19.057
Allergan Inc. 0.8774 0.9495 65 602.900 229.400
Edwards 0.7569 0.7830 61 351.800 203.600
Lifesciences Corp
NuVasive Inc. 0.8824 0.8000 60 56.239 107.577
Bristol-Myers Squibb Co. 0.7731 0.9367 59 4,420.000 1,204.000
Masimo Corp. 0.7207 0.6729 59 113.241 45.028
Colgate-Palmolive Co. 0.6141 0.8590 55 6,006.000 1,222.000
Tornier NV 0.7892 0.8040 55 47.937 77.525
CONMED Corp. 0.5517 0.7862 53 319.934 172.796
Amgen Inc. 0.9006 0.9096 52 1,497.000 2,022.000
Invacare Corp. 0.3173 0.8122 50 1,175.636 174.375
Zoll Medical Corp 0.5887 0.7137 49 182.604 69.958
Covidien Plc. 0.6067 0.9138 48 4,102.000 1,381.000
Stryker Corp. 0.7102 0.7554 48 2,121.100 1,056.800
Taro Pharmaceutical 0.6425 0.7570 46 140.330 83.709
Industries Ltd
Mindray Medical 0.6078 0.8520 43 276.262 79.185
International Ltd.
Integra LifeSciences 0.6764 0.7958 42 236.926 146.928
Holdings Corp
Merit Medical 0.4831 0.8093 42 153.401 60.597
Systems Inc
Elan Corp PLC 0.5554 0.9657 39 520.000 39.000
Intuitive Surgical Inc. 0.7575 0.9278 39 342.600 86.800
Warner Chilcott Plc. 0.8635 0.9740 38 405.878 119.497
Hologic Inc. 0.6549 0.9592 35 579.654 192.482
L’Oreal S.A. 0.7472 0.9040 34 6,540.025 2,401.821
Shire PLC. 0.8862 0.9310 34 394.900 260.000
Table A.2: Data
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Firm GM CI PV COGS IL
ProPhase Labs Inc 0.6339 0.7793 32 5.309 1.682
Alphatec Holdings Inc 0.7550 0.8312 31 42.047 51.635
ICU Medical Inc. 0.5198 0.7032 31 136.644 44.056
Sirona Dental 0.6254 0.9388 30 288.542 74.027
American Bio 0.4363 0.2953 29 5.874 3.604
Medica Corp.
OraSure Technologies Inc 0.6715 0.7731 29 24.645 7.346
Hemagen Diagnostics Inc. 0.4828 0.3025 28 2.700 1.386
Hospira Inc. 0.4702 0.7888 27 2,075.200 955.500
NxStage Medical Inc. 0.4036 0.7889 27 106.891 34.950
BIOLASE Technology Inc. 0.3773 0.3757 26 16.330 6.987
Cephalon Inc. 0.8655 0.9039 26 377.963 291.360
Quidel Corp. 0.5916 0.8995 25 46.289 17.707
CCA Industries Inc. 0.5727 0.3272 23 21.580 9.076
Corgenix Medical Corp. 0.6155 0.4012 23 3.175 2.500
Endo Pharmaceuticals 0.7487 0.9345 23 431.353 178.805
Holdings Inc.
Syneron Medical Ltd. 0.5161 0.8362 23 91.718 22.720
Akorn Inc. 0.5323 0.6647 22 40.411 18.917
Given Imaging Ltd. 0.8191 0.8088 22 28.540 19.076
Palomar Medical 0.6614 0.7974 22 21.578 13.021
Technologies Inc.
SonoSite Inc. 0.7413 0.7503 22 71.240 37.126
Kensey Nash Corp. 0.7922 0.8770 21 16.755 8.886
Spectranetics Corp. 0.7935 0.8111 21 24.345 8.054
Teleflex Inc. 0.4919 0.8894 21 915.447 338.598
Bard (C.R.) Inc. 0.6648 0.8417 19 911.900 308.900
Orthovita Inc. 0.6759 0.5522 18 30.681 22.035
Volcano Corp. 0.6848 0.7246 18 92.720 40.499
Table A.3: Data
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Firm GM CI PV COGS IL
Cambridge Heart Inc. 0.3193 0.4409 17 1.919 0.686
Stereotaxis Inc. 0.7477 0.5469 17 13.637 5.441
Accuray Inc. 0.5026 0.4646 16 110.227 28.186
Allied Healthcare 0.2705 0.4725 16 33.580 11.156
Products Inc.
AtriCure Inc. 0.8093 0.3507 16 11.255 5.680
Estee Lauder 0.8002 0.7282 16 1,560.600 826.600
Companies Inc.
CAS Medical 0.4461 0.3383 15 13.341 4.813
Systems Inc.
Gen-Probe Inc. 0.7549 0.9213 15 133.178 66.416
Kinetic Concepts Inc. 0.6205 0.9244 15 765.656 172.552
LeMaitre Vascular Inc. 0.7687 0.7086 15 12.965 8.375
Mako Surgical Corp. 0.6004 0.7929 15 17.701 10.504
Meridian Bioscience Inc. 0.6515 0.6848 15 49.840 27.965
Salix Pharmaceuticals Ltd. 0.8049 0.9121 15 65.732 16.021
Trimedyne Inc. 0.3923 0.3729 15 3.890 2.613
Gilead Sciences Inc. 0.7808 0.8302 14 1,742.736 1,203.809
CareFusion Corp. 0.5190 0.9279 13 1,890.000 422.000
IRIDEX Corp. 0.4902 0.2362 13 22.276 9.212
Rochester Medical Corp. 0.5262 0.6978 13 19.637 9.240
Utah Medical 0.5500 0.8386 13 11.305 3.097
Products Inc.
Digirad Corp. 0.2816 0.6009 12 40.364 5.432
Natus Medical Inc. 0.6412 0.8430 12 78.461 37.627
Cardica Inc. 0.2838 0.5688 11 2.851 1.131
Cutera Inc. 0.5806 0.5641 11 22.341 6.448
Dynatronics Corp. 0.3950 0.4372 11 19.942 5.767
Table A.4: Data
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Firm GM CI PV COGS IL
Medicis Pharmaceutical Corp. 0.9000 0.9040 11 69.981 39.777
Orthofix International NV 0.7963 0.7755 11 114.958 84.589
Regeneration Technologies Inc. 0.5025 0.4331 11 82.670 87.278
Bovie Medical Corp. 0.4537 0.6286 10 13.236 7.605
Cornerstone Therapeutics Inc. 0.6408 0.8994 10 45.015 15.174
Derma Sciences Inc. 0.3085 0.5904 10 39.051 12.499
ATRION Corp. 0.5338 0.8261 9 50.614 17.400
Celgene Corp. 0.9308 0.9573 9 251.018 260.130
Paradigm Medical 0.5771 0.4019 9 0.307 0.509
Industries Inc.
Synergetics USA Inc. 0.6114 0.7293 9 20.234 11.891
Cardiovascular Systems Inc. 0.7778 0.4717 8 14.403 4.319
Columbia Laboratories Inc. 0.6935 0.2795 8 8.769 2.586
Retractable Technologies Inc. 0.3878 0.5990 8 22.173 8.682
Span-America Medical 0.3863 0.7149 8 32.131 4.135
Systems Inc.
Hansen Medical Inc. 0.3484 0.6793 7 10.838 6.232
Rockwell Medical 0.1889 0.5942 6 48.304 2.937
Technologies Inc.
United Therapeutics Corp. 0.9101 0.9494 6 54.265 35.520
Amylin Pharmaceuticals Inc. 0.6097 0.8782 5 261.014 118.629
Chembio Diagnostics Inc. 0.5019 0.5179 5 8.320 1.349
Electromed Inc. 0.7654 0.7617 5 3.356 1.471
Fonar Corp. 0.4601 0.6915 5 17.176 3.103
SeraCare Life 0.4337 0.5442 5 28.53 9.029
Sciences Inc.
Trinity Biotech PLC 0.5302 0.7721 5 42.871 17.576
Table A.5: Data
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